

## Index

### a

- abatacept 1343
- Abl-family tyrosine kinase
  - inhibitor 1586
- absent in melanoma 2 (AIM2) 31
  - like receptor 997
  - types 138
- acetylcholine (ACh) 1486
  - neuronal receptors 1499
  - T lymphocytes 1487
- acetylcholinesterase (AChE)
  - inhibitors 1495
- acetyltransferase 233
- acidosis 224, 894
- ACKR1/DARC expressed by
  - erythrocytes 635
- activated partial thromboplastin time (aPTT) 834
- activated protein C (APC) 464, 739, 838
- activating transcription factor 3 (Atf3) 1448
- activation-induced cell death (AICD) 1055
- activator protein 1 (AP-1) 231, 975, 1473
- acute inflammation 695
  - conditions, genetic susceptibility 1331
  - inflammatory responses 1447
- acute kidney injury (AKI) 1301
- acute lung injury (ALI) 790, 796, 797
- acute-phase proteins 1350
- acute-phase reactants 1542
- acute-phase response (APR) 861, 1350
- Acute Physiology and Chronic Health Evaluation (APACHE-II) 847
- acute rejection
  - antibody-mediated 1157
  - caused by T lymphocytes 1157
- acute respiratory distress syndrome (ARDS) 795
- ADAMTS13 activity 837
- adaptive immunity 785, 876, 1147
  - antigen recognition by T cell 1005
  - B-cell activation 1012
  - central and peripheral tolerance mechanisms 1004
  - complement, role in 790
  - immune cells, activators of 791
  - immune responses 9, 273, 818, 947, 1092, 1147, 1316
    - to allografts, immediate 1155
    - inflammation triggered 1666
  - immune systems 1583
  - immunoglobulins 1014
  - other B-cell functions/B-cell subsets 1015
  - regulatory T cells (Tregs) 1010
  - rheumatoid arthritis patients 1113
    - B-cell 1114
    - T cells 1113
  - T cell subsets 1006
  - T follicular helper cells 1010
  - Th1/Th2 paradigm 1006
  - Th17 cells 1009
  - Th22 cells 1010
  - Th9 cells 1010
  - Th2 immunity 347

- adaptive lymphocytes 342  
 adaptive responses to transplants 1156  
 adenosine A3 receptor 957  
 adenosine diphosphate (ADP) 973  
   ribose moiety 87  
   ribosylates Rho 87  
 adenosine triphosphate (ATP) 999,  
   1283, 1313  
   ATPase 1306  
     dependent sodium pumps 1302  
   binding cassette transporters 1280  
   demand 1318  
   dependent molecular  
     chaperones 817  
 adenylate cyclase toxin CyaA 85  
 adherens junctions 442  
   components 470  
 adherent platelets 423  
 adhesion molecules 1154, 1521  
   on colonic endothelial cells 461  
 adipocytes 327, 1228  
 adipokines 922, 1235  
 adiponectin 924  
   dendritic cells 924  
   lymphocytes 924  
   macrophages 924  
   neutrophils 924  
   NK cells 924  
 adipose-derived stem cell 1205  
 adipose inflammation  
   impact on local biology 1205  
   obesity complications 1206  
 adipose tissue 1199, 1226, 1227  
   inflammation, in obesity 1202  
 adipsia 861  
 adjuvants  
   adjuvant system 3 (AS03) 147  
   aluminum compounds 144  
   combinations 157  
   for human use 144  
   induced peripheral  
     inflammation 655  
 ADM. *see* adrenomedullin (ADM)  
 ADP. *see* adenosine diphosphate  
   (ADP)  
 adrenergic receptors (ARs) 1497  
 $\beta$ 2-adrenergic receptors ( $\beta$ 2ARs) 1500  
 adrenocorticotrophic hormone  
   (ACTH) 917, 1430, 1488,  
   1489  
 adrenomedullin (ADM) 1549  
   antibody 1595  
   MR-proADM, elevated levels 1550  
 advanced glycation end product  
   (AGE) 1239  
   AGE-RAGE axis 1239  
 aeroallergen 185  
 afferent neuronal signals 873  
 afferent vagus 873  
 age-related macular degeneration  
   (AMD) 1354  
 aging 713, 1226  
   IL37-tg mice 506  
   physiological process of 696  
 Aicardi-Goutieres syndrome 188  
 AIM2. *see* absent in melanoma 2 (AIM2)  
 airway epithelium, response to  
   allergens 998  
 airway hyperresponsiveness 504  
 Akt/protein kinase B (Akt/PKB)  
   1230, 1231, 1672  
 aldehyde dehydrogenase 292  
 aldolase 818  
 aldosterone 917  
 alkylthiyl radicals (R-S $\bullet$ ) 706  
 alkyne-containing jadomycin 1675  
 allergen sensitization 1000  
 allergen-specific IgE antibodies 996  
 allergic asthma 292  
 allergic disorders 375, 995  
 allergic inflammation 374, 996, 997,  
   1004  
   antigen recognition by T cell 1005  
   B-cell activation and fate 1012  
   central and peripheral tolerance  
     mechanisms 1004  
   cytokines 1015–1017  
   immunoglobulins 1012, 1014  
   inflammatory response,  
     mechanism 996  
   other B-cell functions and B-cell  
     subsets 1015  
   regulatory T cells (Tregs) 1010  
   T cell subsets 1006

- T follicular helper cells 1010  
 Th9 cells 1010  
 Th17 cells 1009  
 Th22 cells 1010  
 Th1/Th2 paradigm 1006  
 allergic rhinitis 347, 559  
 allergic sensitization 798, 999  
 allergy, classical 995  
 alloantigens 1151  
 allodynia 676  
 alloimmunity 1054, 1150  
 allosteric effects 633  
 alpha-1-antitrypsin 749  
   anti-inflammatory properties 490  
 alternatively activated macrophage  
   (AAM) 345  
 alternative pathway (ACP) 1354  
 alum 144  
 aluminum phosphate 144  
 aluminum salt combination (AS04)  
   adjuvant 145  
 alveolar macrophages 185, 949  
 Alzheimer's disease 1489, 1502  
   patients with AChE inhibitors 1502  
 American College of Rheumatology  
   (ACR) 555  
 aminoalkyl glucosaminide 4-phosphate  
   (AGP) 154  
 amino-hexoses 22  
 aminotransferase-to-platelet ratio  
   index 676  
 AMP-activated protein kinase  
   (AMPK) 1384  
 amphibians 1517  
 amphiregulin 345  
 amplification pathway 787  
 amyloid- $\beta$  (A $\beta$ ) deposits 1258  
 anabolic pathways 976  
 anakinra (IL-1 receptor  
   antagonist) 482  
 anaphylatoxin 10, 786–791  
   C3a 63  
 anastomosis 229  
*Androctonus australis hector*  
   venom 106  
 androgens 919  
 angioedema 803  
 angiogenesis 229, 457, 465, 1118  
   LPA and S1P, role of 674  
 angiogenin (ANG) 4 441  
   stimuli 467  
 angiotensin II 1233  
 ankylosing spondylitis 1116  
 anoikis 738  
 anorexia 657, 861  
 anthrax 8  
 anti-allergy treatment 662  
 antiapoptotic  
   factors 529  
   signals 592  
 anti-B and T lymphocyte attenuator  
   (BTLA) 1596  
 antibiotherapy 265  
 antibiotics 1584  
   treatment 1545  
 antibodies (Abs) 1592  
   allergen-specific IgE 996  
   anti-APC 464  
   anti-HMGB1 60  
   anti-HSP60 IgG-type 818  
   anti-IFN $\gamma$  37  
   anti-OX40 539  
   C5 blocking 803  
   complement, activation 801  
   dependent cellular cytotoxicity 995,  
     1015  
   mediated autoimmune diseases 367  
   production 792  
 anti-CD25-mediated T<sub>REG</sub>  
   depletion 1398  
 anticitrullinated peptide antibodies  
   (APCA) 1107  
 anticytokine 482  
 antifibrotic effects 1355  
 antigen-presenting cell (APC) 84, 144,  
   659, 791, 792, 1112, 1151,  
   1379  
   on inflammation 839  
 antigens 439, 824  
   Ag-presenting molecules 154  
   Ag-specific humoral immunity 156  
   Ag-specific T-cell 155  
   Ag uptake 147  
   allergen-specific memory 996

- antigens (*Continued*)
  - B-cell selection, in germinal centers 1391
  - driven expansion 319
  - expression of transplant 1148
  - glucose-lipid 21
  - independent activation
    - mediators 1152
  - nonspecific inflammation 1147, 1148
  - presentation
    - in context of MHC class I 1007
    - in context of MHC class II 1008
    - transplant 1150
  - self 818
  - shuttling 792
  - specific adaptive immune responses 1147
  - specific CD8<sup>+</sup> T-cell (CTL) responses 151
  - specific self-tolerance 1094
- anti-IL2R $\alpha$  (Daclizumab) 352
- anti-inflammatory 795
  - activities 1001, 1668, 1670, 1673, 1674
  - adipokine 1227
  - cytokines 12, 229, 496, 499, 1163, 1363, 1429, 1488, 1524
    - soluble cytokine receptors 1369
    - soluble decoy toll-like receptors 1371
    - soluble ST2 1371
    - soluble TREM-2 1372
    - toll-like receptor-mediated immune responses 1369
  - drug 265, 1674
  - growth factor 467
  - master 1228
  - mechanisms 1372
    - genes/proteins 1351
  - mediators 1523
  - monocyte subsets 1524
  - properties 499, 601
  - responses 1500
  - stimuli 234
- antimicrobial
  - activities 727
  - chemotherapy 1584
  - itaconate 955
  - peptide 175, 400, 441, 1092
  - proteins 57
- antineutrophil cytoplasm
  - autoantibodies (ANCA) 260, 264
- antinuclear antibodies (ANA) 1073
- antioxidant
  - activity 870
  - free radical scavengers 710
  - harmful or beneficial 712
  - response element 712
  - supplementation 712
- anti-programmed cell death ligand (PDL1) antibody 1596
- anti-T-cell immunity 820
- antithrombin (AT) 837, 838
  - adaptive immune cells 1203
  - levels 837
  - macrophage infiltration 1201, 1203, 1212
    - neutralizes coagulation enzymes 837
- antithymocyte globulin 1163
- antivirulence factor therapies 1584
- anti venom 111
  - inflammation 110–111
  - Myrmecia genus* 111
- anxiety 861
- APC. *see* antigen-presenting cell (APC)
- apocynin 1265
- apolipoprotein E (ApoE)
  - deficient mice 486
  - null mice 665
- apoptosis 299, 738, 917, 949, 959, 1314
  - associated speck-like protein 138
  - differentiation program 262
  - inhibition 1321
- apoptosis-associated speck-like protein containing CARD (ASC) 31
  - knockout 145
- apoptotic cells 228, 789, 1305, 1351
- A proliferation-inducing ligand (APRIL) 1076
  - BlyS receptors transmembrane activator 1076
- arachidonic acid 869, 1449

- metabolism 791
- pathway 1672
- area postrema (AP) 1487, 1489
- arginase activity 956
- L-arginine 459
- aristaless-related homeobox (Arx) 442
- $\beta$ -arrestin 635, 790
- arthritis 1447
  - ischemia-reperfusion experimental models 60
- arthritogenic alphaviruses 1354
- articular diseases 1105
- aryl hydrocarbon receptor nuclear translocator (ARNT) 133
- asparagine endopeptidase (AEP) 735
- aspartic acid (D20)
  - in exon 1 503
- Aspergillus fumigatus* 36, 181, 504, 1353, 1354
- Aspergillus versicolor* 1587
- aspirin 1672
- asthma, allergic 292
- astrocytes 530, 776
- astroglia 1256, 1257
- AT. *see* antithrombin (AT)
- atherogenesis 1283
- atherosclerosis 457, 715, 818, 1199, 1229, 1279–1281
  - macrophage inflammatory pathways in 1291
  - mediators of inflammation 1283
    - chemokines 1286
    - cytokines 1283
    - interferons 1285
    - potential of dietary changes 1286
    - targeting inflammation 1286
  - mouse models of 1280
  - pharmacological intervention 1288
    - activating transcription factor 3 1292
    - anti-TNF therapy 1290
    - CANTOS 1290
    - CIRT 1290
    - ENTRACTE clinical trial 1290
    - JUPITER trial 1289
    - statin therapy 1289
    - targeting IL-1 $\beta$  with Canakinumab 1290
- atopic dermatitis 347, 643, 1099
- ATP. *see* adenosine triphosphate (ATP)
- Atractaspis engandensis* 102
- AT1R/AT2R activation 1235
- ATX-LPA-LPA<sub>1,4,6</sub> axis 674
- atypical chemokine receptors (ACKR) 632, 635
- atypical hemolytic uremic syndrome (aHUS) 1354
- autoantibodies 799, 818, 1316
- autoimmune 821, 1053, 1054, 1094, 1380, 1382, 1391
  - diseases 329, 482, 785, 819, 918, 1055, 1066, 1074
  - monocytes and macrophages 1071
  - disorders 799, 1677
  - hemolytic anemia 995
  - and inflammation 300, 1053
  - injury 1256
  - polyendocrinopathy candidiasis ectodermal dystrophy 1057
  - regulator 1057
  - tissue injury 1053, 1068, 1073
    - B lymphocytes 1069
    - immune complexes 1068
    - lymphocytes 1069
    - monocytes/macrophages 1070
    - systemic autoimmune diseases 1073
    - tertiary lymphoid organs (TLO) 1071
    - T lymphocytes 1069
- autoimmune regulator (AIRE) protein 1057
- autoinflammation 1053, 1054
  - diseases 1365
  - syndrome 482
- autonomic homeostatic reflexes 1490
- autophagocytosis 817
- autophagosome 137, 817
- autophagy 137, 817, 1314
  - associated HLA-B27 misfolding 1120
  - chaperone-mediated 817
  - macroautophagy 817
  - microautophagy 817

- autophosphorylation 589
- autoreactive lymphocytes 1393
- autosomes 137
- avidity 1151
- AXD consensus sequence 504
- azoxymethane-dextran sodium sulfate
  - treatment 659
  
- b**
- Bacillus anthracis* 84, 193, 1587
- Bacillus subtilis* 423
- bacterial
  - antigens 820
  - DNA 156
  - flagellum 28
  - infection 1396, 1545
  - lipoproteins 1588
  - membrane and endosomal Toll-like receptors 32
  - mRNA 32
  - proteases 734
  - replication 187
  - toxins
    - genetics and pathobiology of infections 81
    - pathogenicity by microorganisms 81
- bacterial artificial chromosome (BAC) 1393
- bacterial PAMPs. *See* pathogen-associated molecular patterns (PAMPs)
- bacteriophage therapy 1584
- bacteriotropin 6
- Bacteroides fragilis* 552
- BALB/c mice (BMDCs) 825, 1398, 1399
- B- and T lymphocyte attenuator (BTLA) 1163
- barotrauma 795
- basic helix-loop-helix (bHLH) 442
- basophils 293, 634, 971, 1001
- B-cell 292, 315, 341, 342, 365, 533, 536, 550, 785, 792, 927, 1225, 1226, 1229, 1230, 1233, 1236, 1316, 1343
  - activating factor 536
  - checkpoint mechanisms 1064
  - clonal deletion of 1056
  - deletion 1064
  - developmental stages 1013
  - dysfunction 1232
  - failure 1229, 1233
  - growth factor 590, 1232
  - immune-mediated targeting of 714
  - maturation factor 536
  - receptor 792, 1004, 1063, 1666
  - tolerance 1059
- B-cell-activating factor (BAFF)
  - receptor 536
  - transgenic mice 536
- $\beta$ -cell dysfunction 1232
- bees, inflammation induced by
  - venoms 110–111
- biglycan 66, 1588
  - deficient mice 66
- bioassays 1675
- biochemical signal transduction
  - pathways 424
- bioenergetics 929
  - dendritic cells 929
  - lymphocytes 930
  - macrophages 930
  - neutrophils 930
- biofilm 1584
- bioinformatics 1330
- bioluminescence resonance energy transfer (BRET) 502
- biomarkers 1190
  - for inflammation 1541, 1542
  - panels of combined of 1551
- bleomycin
  - induced lung fibrosis 667
  - induced pulmonary fibrosis 663, 675
- blocking tissue factor activity 835
- blood-borne cytokines signal 1489
- blood-brain barrier (BBB) 538, 771, 772, 862, 870, 1255, 1488
- blood circulation 3
- BLT1 deficiency 665
- BLT2 inflammation, and tissue homeostasis, role in 665
- blunt leukocyte–endothelial cell
  - adhesion 463

- body mass index (BMI) 1226  
body temperature 861  
bone marrow 1065  
    B-cell progenitors 506  
    derived mast cell 276  
    stromal cells 598  
bone morphogenetic protein (BMP) 1121  
*Bordetella pertussis* 84  
*Bothrops* snake 103  
    bitten victims 100  
    *Bothrops asper* snake venom 101,  
    104  
    *Bothrops jararaca* 102  
    *Bothrops moojeni* venoms 102  
    venom 100, 102, 103  
    induced inflammation 105  
    induced leukocyte 102  
BoTXC3 676  
Bowman's space 1078  
bradykinin 803  
brain  
    cholinergic muscarinic acetylcholine  
    receptor (mAChR)-mediated  
    signaling 1495, 1501  
    communication 1501  
    controlled symptoms 861  
    derived immunoregulatory  
    mechanisms 1491  
    endothelial cells 872  
    function 1494  
    neurotransmitter systems,  
    dysfunctions 1495  
    nitric oxide synthases 1673  
    plasticity 1526  
    processing of febrile signals in 874  
Braun's lipoprotein 27  
briakinumab 352, 407  
broad-spectrum antibiotics 795  
brodalumab 408, 555, 557  
bronchial hyperresponsiveness 375  
bronchoalveolar lavage (BAL) 675  
    fluid 795  
brown adipose tissue (BAT) 865, 922
- C**  
C3a/C5a receptors 797, 798  
    antibodies 803  
    biological roles 798  
    complement factors 1316  
    convertase 1320  
    convertase formation 786  
    dependent rapid production 873  
E-cadherin 733  
cadherin-related family member 3  
    (CDHR3) 999  
*Caenorhabditis elegans* 814, 1492  
Ca<sup>++</sup> influx 896  
calcitonin gene-related peptide  
    (CGRP) 110, 1493  
calcium 703  
    diffusion neutralizes 440  
    mobilization 789  
    phosphate 145  
calmodulin 703  
calprotectin 64  
calreticulin 789  
*Campylobacter jejuni* 28  
cancer 1199, 1393  
    immune evasion 229  
    immunosurveillance 1393  
*Candida albicans* 36, 181, 376, 1330,  
    1397, 1426  
    infection 1397  
    yeast cells 508  
candidiasis 186  
carbon monoxide 1319  
carboxypeptidase A3 278  
cardiopulmonary bypass 1317  
cardiotrophin 1 (CT-1) 575  
cardiotrophin-like cytokine factor 1  
    (CLCF1) 575  
cardiovascular disease (CVD) 1199,  
    1279, 1285, 1286, 1674  
cartilage proteoglycans 820  
caspases 82, 529  
    activating and recruitment  
    domain 28  
    domains 32  
caspase-1 1364  
    activation 1519  
    deficient mice 486, 491  
    inflammasome 488  
caspase-11 82  
toxins modulating 82

- Castleman disease 578, 582  
 catecholamines 1372, 1489, 1500  
 cathelicidins 278, 446  
     LL-37 expression 446  
 cathepsin 787  
     cathepsin G 732–734  
     cathepsin L 735  
     cathepsin S 735  
 Caucasians 662  
 C4b binding protein (C4bBP) 786, 839  
 C57BL/6-DEREG mice 1398  
 C-C motif ligand 2 (CCL2) 1282  
 CCP. *see* classical complement pathway (CCP)  
 CCR-7  
     axis 636  
     expression 917  
 CD-related inflammation 551  
 CD3<sup>+</sup>CD56<sup>+</sup> cells 317  
 CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup> Tregs 1096  
 CD4<sup>+</sup> Foxp3<sup>+</sup> Treg cells 1203  
 CD4<sup>+</sup> T cells 530, 633, 1151, 1368, 1372  
     helper T cells 534  
     naïve T cells 1381  
     OX40-OX40L signaling in 536  
     population 398  
 CD8 coreceptor, on cytotoxic T cells 1150  
 CD8 memory 1398  
     T-cell pool 1396  
 CD8<sup>+</sup> T-cell memory 152, 280, 323, 530, 595, 1397  
 CD11c stain:CD11c<sup>+</sup> myeloid dendritic cell accumulation 1093  
 CD14<sup>++</sup>CD16<sup>+</sup> monocytes 1001  
 CD14/CD14 receptors 1547  
 CD14-dependent fashion 26  
 CD14 expression 920  
 CD18-ICAM-1 interactions 463  
 CD18 immunoblockade 463  
 CD25<sup>+</sup>Foxp3<sup>+</sup> cells 1383  
 CD25-targeted diphtheria toxin 1394  
 CD25<sup>+</sup>Foxp3<sup>-</sup> thymocyte precursors 1379  
 CD28 expression 1380  
 CD28 homodimer interface 1598  
 CD36 expression 1291  
 CD40 antibody 660  
 CD56<sup>bright</sup> NK cells 317  
 CD62 ligand (CD62L) 1064  
 CD64, neutrophil expression 1550, 1551  
 CD64 values 1551  
 CD80, to T-cell-expressed CD28 590  
 CD94-NKG2A heterodimers 324  
 CD103, in Balb/c mice 1398  
 CD146, endothelial expression of 470  
 cDNA cloning 487  
 cecal ligation and puncture (CLP) 27, 60  
 celecoxib 658  
 cell  
     activation 651  
     adhesion molecules 461, 715, 1549  
     apoptosis 916  
     contact-dependent suppression 1060  
     death 1313, 1314  
     demise 1313  
     forming BBB 871  
     function 1313  
     hypoxia 129  
     immune response 587  
     integrity 1284  
     interaction 404  
     mediated abnormal wound healing 675  
     necrosis 706  
     penetrating peptides 1590  
     proliferation 175  
     respiration 131  
     signaling pathways  
         in inflammation 1667  
         schematic representation 1664  
     sources 484  
     stress 814  
         markers of 813  
     surface antigens 26  
     surface markers, and signature transcription factors 316  
     cell-cell contact 733, 735  
     cell-cell interactions 1111  
     central nervous system (CNS) 1255, 1485



- centruroides noxius 106
- cerebrospinal fluid (CSF) 1372
- C1 esterase inhibitor 802
- C3 exoenzyme of *Clostridium botulinum* (C3bot) 87
- c-Fos mapping 657
- C3 glomerulonephritis 799
- C3 glomerulopathy 800
- chaperones 813, 816
- Charcot's joints 1567
- ChAT. *see* choline acetyltransferase (ChAT)
- chemoattractant 57, 257, 279, 619, 627
- protein 792
- receptor CRTH2 344
- chemokines 60, 175, 223, 227, 256, 366, 404, 554, 619, 626, 628, 631, 732, 875, 962, 1233, 1256, 1486, 1520, 1521
- CCL1-CCR8 axis 641
- CCL20 functions 1096, 1097
- CC receptor (CCR)7 1386
- CCR6 expression 1097, 1388
- CCR9 ligand 636
- clusters 628
- CXCR2, on neutrophils 107
- dual function 628
- family 1520
- glycosaminoglycan interactions 1524
- inflammatory 627, 628
- ligand (CCL) 3 and 4 1552
- monomer, ribbon diagrams 630
- motif ligand 2 (CCL2), matrix 1201
- organ development 636
- receptors 219, 629, 632, 633, 639, 640, 642, 1486
- activation, two-step model 633
- expression by T-cell subsets 629
- nomenclature systems 626
- schematic depiction 632
- recognition site 1 633
- scavenger 635
- superfamily, clinical applications 642
- synthesis 1523
- chemotaxis 7, 619, 1549
- inhibitory protein of staphylococci 958
- ChemR23, expressing cells 1453
- chikungunya virus 1354
- chimeric antigen receptor (CAR) 1399
- Chlamydia-infected cells 65
- Chlamydia pneumoniae* 191, 958
- HSP60 31
- chloride ion secretion 439
- cholesterol 1279, 1280
- containing membranes 82
- crystals 1283
- in vitro* 1283
- hypercholesterolemia 1190, 1451
- transport 1280
- choline acetyltransferase (ChAT) 1499
- expressing 1491
- cholinergic
- anti-inflammatory 1491
- signals 1490
- chondroitin sulfate 277
- chromatin
- immunoprecipitation-sequencing 232
- remodeling 1431
- structure, and function 974
- chromoblastomycosis 195
- chromosome 1q23.2 locus 1351
- chronic granulomatous disease (CGD) 1266
- chronic obstructive pulmonary disease (COPD) 953, 1173
- accelerated aging and inflammation in 1188
- associated with
- chronic inflammation 1173
- indoor air pollution 1174
- central role of alveolar macrophages in 1178
- defective resolution of inflammation and repair 1187
- accelerated aging 1188
- airway fibrosis 1189
- proresolving lipid mediators 1187
- eosinophilic inflammation in 1180
- future implications 1189

- chronic obstructive pulmonary disease (COPD) (*Continued*)
  - inflammasome activation in 1184
  - inflammatory cells 1175
    - dendritic cells 1182
    - eosinophils 1180
    - epithelial cells 1175
    - lymphocytes 1181
    - macrophages 1176
    - neutrophils 1179
  - inflammatory mediators 1183
    - chemokines 1185
    - cytokines 1183
    - inflammasome 1184
    - lipid mediators 1183
    - proteases 1185
  - lymphocytes in 1182
  - mucus hypersecretion and hyperplasia in 1177
  - oxidative stress, as a major driving mechanism 1185
  - pathology of 1174
  - systemic inflammation in 1187
- chymases 733
- chymotrypsin 733
- ciliary neurotrophic factor (CNTF) 575
- circulating
  - neutrophils 1201
  - pyrogens 871
- citrate metabolism 955
- Citrobacter rodentium* 193, 1397
- citrulline 703, 956
  - specific B cells 1114
- c-Kit inhibitor 1118
- classical complement pathway (CCP) 1354
  - deposition 1355
- claudin 4 666
- clonal deletion 1056, 1057
- Clostridium botulinum* 86
- Clostridium difficile* 88, 193, 1334
  - associated colitis 1593
- clumping factor A (ClfA) 423
- cmv-1 gene 322
- coagglutination system 787
- coagulant 739
- coagulation
  - abnormalities 847
    - treatment during severe inflammation 847
  - modifications 862
  - proteases 841
  - proteins 845
- coagulopathy, associated 833
- colitis
  - associated colon cancer 659
  - chronic, T-cell transfer model 460
  - enhanced thrombogenic response 465
    - mice deficient in IL-1R8 502
- collagen-induced arthritis (CIA) 556, 657
- colonic arterioles 460
- colony-stimulating factor-1 (CSF-1) 220
- colorectal cancer (CRC) 659
- Colubridae (*sensu lato*) 100
- commensal microbiota 292
- common helper ILCP (CHILP) 342
- common lymphoid progenitor (CLP) 342
- compensatory anti-inflammatory response syndrome (CARS) 1428
- complement
  - activation 785, 786, 791, 795
    - anaphylatoxin receptors 789
    - antibodies 801
    - opsonin receptors 788
  - adaptive immunity and chronic inflammation 792
  - adaptive inflammatory response, role in 791
  - cascade 870
  - continued 792
  - fragments of 794
    - C5a 869
  - in human diseases, role of 799
    - vasculitis 799
  - innate immunity and acute inflammation 790
  - innate inflammatory response, role in 791
  - intracellular, evidence 793

- pathways 785, 786
  - alternative 786
  - classical 786
  - lectin 786
- products 787, 788
  - receptors for 788
- proteins
  - C3 732
  - fragmentation of 787
  - receptors 788, 792, 793
  - strategies to block 802
  - system 785, 1238
  - uncontrolled 792
- complementary and alternative medicine (CAM) 1661
- complete Freund's adjuvant (CFA) 146
- compstatin 802
- computational networks 1677
- computed tomography 1567
- confidence interval (CI) 848
- connective tissue growth factor (CTGF) 676
- constitutive production of CCL27 (CTACK) 1092
- contact hypersensitivity (CHS) 283
- conventional dendritic cells (CD11b<sup>-</sup> and CD11b<sup>+</sup>) 1143
- conventional imaging techniques 1567
- conventional myeloid dendritic cells (cDC) 1112
- convertases 786
- Coombs test 995
- COPD. *see* chronic obstructive pulmonary disease (COPD)
- coreceptor IL-1R3 499
- coreceptor neuropilin-1 467
- cortical thymic epithelial cells, self-peptide/MHC complex 1065
- corticosteroids 1189
  - biosynthesis 1468
  - pathways 1468
- corticosterone 1430
- corticotropin releasing factor (CRF) 655, 899
  - receptor 899
- corticotropin-releasing hormone (CRH) 1470, 1488
  - induced IL-2 receptor expression 918
- cortisone 1470
- Corynebacterium parvum* 1426
- COX. *see* cyclooxygenase (COX)
- C-reactive protein (CRP) 10, 482, 768, 1349, 1351, 1352, 1354, 1542, 1543
  - CRP gene 1351
  - values 1543
- Crohn's colitis 461
- Crohn's disease (CD) 65, 352, 374, 400, 403, 445, 457, 460, 493, 537, 661, 1141, 1336, 1399, 1478
  - immunodeficiencies in phagocytes as cause 1143
  - missing heritability 1141
  - patients 446
- Cromolyn 283
- Crotalus atrox* snake venom 104
- crown-like structure 1203
- CRP. *see* C-reactive protein (CRP)
- cryoglobulinemia 1069
- cryopyrin-associated periodic syndrome (CAPS) 482
- cryopyrinopathies 193
- crypt base columnar (CBC) 438
- Cryptococcus neoformans* 1397
- cryptopatches 344, 348
- crystallographic studies 1149
- crystal structures of GPCRs 643
- C-terminal pentraxin domain 1352
- CTLA-4-dependent regulation 1392
- C-type lectin receptors (CLRs) 144, 181–183, 225, 997, 1263, 1369
  - dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) 181
  - mannose receptor 182
  - signaling pathway 187
  - surfactant protein-D 182
- cutaneous anaphylaxis 666
- cutaneous lymphocyte antigen (CLA) 376, 1091
  - CLA<sup>+</sup> recirculating T cells 1092
- C-X-C motif (CXC) ligand 1
  - chemokines 445

- cyclic adenosine monophosphate
  - (cAMP) 459, 789
  - intracellular levels, toxins
    - modulating 84
  - signaling pathway 84, 660
    - PKA-CREB/CRTC2 pathway 660
- cyclic guanosine monophosphate
  - (cGMP) 459
- cyclooxygenase (COX) 228, 1451, 1672
  - chemokines 630, 631
  - CX3CL1-CX3CR1 axis 632
  - CXCL12-CXCR4 interactions 636
  - CXCL12 gradient 636
  - CXCL8 secretion 603
  - CXCL12/Stromal Cell Derived Factor (SDF-1) 1520
  - cyclooxygenase-2 (COX-2) 538, 868, 1588
    - dependent manner 1457
    - enzyme system 104
    - expression, cytokine-induced 658
    - PGE<sub>2</sub> production 872
  - inhibitors 701, 874, 877
  - pathway 106
  - targeting, using NSAIDs 1267
- cyclophilin ligand interactor 536
- cyclosporine A 1673, 1674
  - triggered cAMP signaling 85
- CysLT receptors 664
  - acute and chronic inflammation, role in 666
- cystathionine  $\beta$ -synthase (CBS) 707
- cysteine 619, 707
  - signal transducing element 709
- cysteinyl leukotrienes (CsyLT) 185, 965
- cystic fibrosis (CF) 265
- cystic fibrosis transmembrane conductance regulator (CFTR) 440
- cytochrome C 131
- cytochrome P450 700
  - myeloperoxidase 916
- cytokines 11, 175, 227, 366, 395, 465, 469, 573, 587, 590, 593, 862, 868, 869, 875, 915, 921, 963, 1283, 1331, 1364, 1521
  - binding 573
  - and chemokines related to Th17 cells 399
  - chemotactic 103
  - dual-function 506
  - gene expression 261
  - inflammatory 257, 1523
  - interleukin-1 family
    - IL-1 $\alpha$  dual-function 484
    - IL-1 superfamily 479
  - interleukin-12 family of 149, 539, 1368
  - like factor 576
  - missense coding mutations 508
  - production 365
  - receptors 589, 1369
    - interactions 588
    - signal 589
  - secretion 365
  - storm 798
  - synergizing 587
  - synthesis inhibitory factor (CSIF) 601
  - type I 961
  - type II 961
- cytokine superfamilies 589
  - common beta chain 592
    - granulocyte colony-stimulating factor (G-CSF) 594
    - IL-3 593
    - IL-5 593
  - common gamma chain 589
  - GM-CSF signals 594
  - granulocyte colony-stimulating factor (GCSF) 598
- interferons 599
  - type I IFNs 599
  - type II IFN $\gamma$  600
  - type III IFN $\lambda$ -1/2/3 600
- networks in cellular immunity 603
- orphan type I cytokines 596
  - IL-13 597
  - IL-14 597
  - IL-32 597
  - IL-34 597
- macrophage colony-stimulating factor 598

- type I cytokine superfamily 589, 961
  - type II superfamily 598, 961
  - cytomegalovirus (CMV) 34, 322
  - cytoplasmic receptors, bacterial DNA and RNA 33
  - cytosine plus guanine (CpG) oligonucleotide 61
  - cytosolic free radicals 132
  - cytotoxic
    - CD90.1-specific antibody 823
    - lymphocytes 996
    - necrotizing factor 88
    - NK cells 318
    - proteins 259
    - soluble factors 1255
    - T cells 144, 148, 534, 1062
      - antigen 4 1065
      - response 235
- d**
- Daboia russelli* snake venoms 104
  - damage-associated molecular pattern (DAMP) 20, 57, 105, 175, 821, 922, 956, 997, 1152, 1153, 1304, 1423, 1485, 1583, 1587, 1588
    - adenosine triphosphate 63
    - agents targeting host responses 1589
    - biglycan 66
    - danger signal receptors 58
    - eosinophil-derived neurotoxin 66
    - heat shock protein 61
    - heme 65
    - heparan sulfate 66
    - high-mobility group box 1 60
    - histones 62
    - hyaluronan 65
    - immunology, definition of 57
    - interleukin-1 $\alpha$ /interleukin-33 64
    - mitochondria 62
    - to modulate immune responses to transplants 1153
    - molecule 1591
    - necrosis vs. apoptosis 58
    - peroxiredoxin 67
    - RNA/DNA 62
    - S100A8/ S100A9 64
    - uric acid crystals 63
  - DAMP. *see* damage-associated molecular pattern (DAMP)
  - danger-associated molecular pattern (DAMP) 137, 791, 1279, 1369, 1541
  - Darwinian evolution principles 971
  - DC. *see* dendritic cell (DC)
  - death domain (DD) 179, 529, 533
  - decay-accelerating activity (DAA) 787
  - decay accelerating factor (DAF) 786
  - decision-making processes 587
  - deep vein thrombosis (DVT) 464
  - defensins 1587
  - degradation pathway, for LPA and S1P 674
  - dehydrocorticosterone 11
  - demethylase 233
  - dendritic cell (DC) 177, 179, 226, 289, 295, 322, 347, 401, 404, 530, 628, 629, 636, 640, 793, 824, 876, 971, 996, 999, 1061, 1092, 1094, 1096, 1150–1152, 1351
    - activation, CTLA-4-dependent suppression 1378
    - in allergic inflammation 292, 298
    - for effector Th2 immune responses to allergens 294
    - immunoreceptor 185
    - induce Th2 immunity, different subtypes 293
    - inflammatory 1096, 1151
      - Fc $\epsilon$ R1<sup>+</sup> DCs 298
    - medullary 637
    - necessary and sufficient for induction of Th2 immunity 292
    - subsets 290
    - T-cell
      - interaction 1112
      - polarization 291
  - denitrification 704
  - dense deposit disease 799, 800
  - dephosphorylation 674, 813
  - depletion of regulatory T cell 1379
  - DEREG model 1397
  - DEREG mouse strain 1393

- dermatitis 376
- Dermatophagoides pteronyssinus* 375
- dermis 1091
- developmental endothelial locus (Del) 1524
- developmental steps, of new imaging agents 1579
- dexamethasone 222
- dextran sodium sulfate (DSS) 460, 484, 552, 663
  - colitis 464, 494, 557
- diabetes mellitus 714, 1199, 1229, 1488
  - metabolic syndrome 505
  - type 1 714, 1225
  - type 2 1225, 1226, 1228, 1231–1233, 1672
    - inflammation causing vascular disease in 1234
    - nonpharmacological management of inflammation in 1240
    - obesity associated inflammation in 1236
- diacylglycerol (DAG) 1666
- diaminopimelate (DAP) 28
- diapedesis 6, 627
- dicarbonyl compounds 1239
- dietary antioxidants 710
- dietary polyphenols 711
- dietary thiols 708
- diet-induced obese (DIO) mice 1202
- digoxin 408
- dimerization 178
- diphenylene iodonium 1265
- diphtheria-tetanus-pertussis (DTP) 144
- diphtheria toxin receptor (DTR) 1378
- disease-modifying antirheumatic drug (DMARD) 557
- disintegrin 631
- disseminated intravascular coagulation (DIC) 425, 833
- DNA
  - binding protein 1592
  - binding transcription factor RBPj 445
  - binding trimer 814
  - damage 318
  - decondensation 732
  - methylation 1189
  - repair mechanisms 707
  - sensing molecules 193–195
    - cross-talk between PRRs 195
    - signaling components of DNA sensing molecules 194
  - vaccine encoding HER2/neu adjuvanted 155
- DNAX accessory molecule-1 (DNAM-1) 318
- DNAX activation protein 12 kDa in size (DAP-12) 1372, 1591
- docosapentaenoic acid (DPA) 1457
- dopamine receptor D2 767
- dopamine signals 1500
- dorsal motor nucleus (DMN) 1490
  - of the vagus 1487
- dorsomedial hypothalamus (DMH) 865
- double-stranded RNA (dsRNA) 178
- Drosophila melanogaster* 30
- drug development
  - antivirulence factor therapy/quorum-sensing inhibitors 1586
  - defensins/antibacterial peptides 1587
  - engineered liposomes to clear exotoxins 1586
  - new antibiotic combinations 1586
  - PAMPs 1584
  - tyrosine kinase inhibitors 1586
- dupilumab 1098
- dysbiosis 441
- e**
  - early ILC progenitor (EILP) 342
  - EC. *see* endothelial cell (EC)
  - ectopic fat 1227
  - ectromelia virus 317
  - Eculizumab 803
  - edema factor (EF) 84
  - edema formation, PGI<sub>2</sub>-IP pathway role 654
  - edema toxin (ET) 84
  - effector memory T cells (T<sub>EM</sub>) 639
  - effector phase 790
  - efferocytosis 6, 366

- EGFR. *see* epithelial growth factor receptor (EGFR)
- eicosanoid oxidoreductase (EOR) 1453
- eicosanoid production 791
- eicosapentaenoic acid (EPA) 1451
- elastase 732, 733
- electron paramagnetic resonance (EPR) 696
- electron spin resonance (ESR) 696
- electron transport chain (ETC) 129  
     reactive oxygen species, formation of 130
- electrostatic interactions 633
- emphysema 1188
- emulsions  
     IFA and CFA 146  
     MF59 146
- encode erythropoietin (EPO) 1321
- ENCODE project 1142
- endocannabinoids 875
- endocarditis 1567
- endocytosed bacteria 278
- endocytosis 635
- endogenous  
     adjuvants 143  
     antinociceptive mechanisms 899  
     antioxidants 711  
     cytokine inhibitors 1523  
     opioid receptor ligands 898  
     protease inhibitors 730  
     pyrogens 862, 875, 1425
- $\beta$ -D-endoglucuronidase heparanase 66
- endometriosis 230
- endopeptidases 727
- endoplasmic reticulum (ER) 88, 974, 1207, 1227
- endosomal/cytoplasmic receptors viral DNA and RNA 34
- endosomes 635
- endothelial barrier function 1595
- endothelial cell (EC) 5, 257, 460, 1150  
     adhesion glycoproteins 461  
     adhesion molecules 461  
         transcription-dependent expression 462  
     dysfunction 457, 458, 464  
     endothelial cell NOS 703, 1672  
     organ-specific responses 844  
     proliferation 466
- endothelial derived relaxing factor (EDRF) 702
- endothelial differentiation gene 2 (EDG2/LPA<sub>1</sub>) 668
- endothelial dysfunction 1235, 1239
- endothelial-leukocyte adhesion molecule 1(ELAM-1) 1474
- endothelial-mesenchymal transition (EndMT) 1118
- endothelial nitric oxide synthase (eNOS) 459, 703
- endothelial protein C receptor (EPCR) 840
- endothelin 875  
     endothelin-1 276, 459, 1189
- endothelium-dependent 458  
     hyperpolarizing factor (EDHF) 459  
     pathways 460
- endotoxemia 62, 1233
- endotoxin 4, 20  
     biochemical characteristics 21  
     cell activation 25  
     chemical structures 22  
     clinical settings 24  
     detection 23  
     historical background 20  
     natural ligands 24  
         shock 61  
     tolerance 21, 26, 234, 1432  
         signature 1428  
     translocation 23
- enterobacteriaceae 22
- envenomation 109
- environmental conditions 861, 863
- enzyme acetyltransferase arrest-defective-1 (ARD1) 134
- enzyme-substrate combinations 1675
- Eomesodermin (Eomes) 316  
     NKp46<sup>+</sup> cell subset 316
- eosinophil 293, 322, 345, 347, 634, 971, 980, 1001, 1204  
     cationic protein 1002  
     derived neurotoxin 1002

- eosinophilia 996, 997
  - esophagitis 374
  - inflammation 292
- EP2/EP4-cAMP-PKA signaling 660
- EP3-expressing MnPO neurons 874
- epidermal cell-derived thymocyte-activating factor (ETAF) 12
- epidermal growth factor (EGF) 230, 439, 734, 840
- epigallocatechin-3-gallate (EGCG) 1671
- epigenetics 971
  - based inflammation treatment 984, 985
  - dysregulation
    - acute inflammation with 978
    - chronic inflammation with 979
  - and immunometabolism 980, 981
  - language 973
  - memory 977
  - poised enhancer-promoter regions 975
  - principles 972
  - successful inflammation 974, 977
  - unsuccessful inflammation 978, 979
- epinephrine (EPI) 1488, 1489
- epithelial cells 437, 438, 998
  - activation 345
  - archetypal epithelial barrier 438
  - cell fate
    - absorptive lineage 438
    - enteroendocrine cells 441
    - goblet cells 439
    - paneth cells 441
    - secretory lineage 439
  - lining 437, 442
  - membranes 443, 1593
  - mucosal barrier protection 1592
- epithelial growth factor receptor (EGFR) 1177
  - amphiregulin ligand 344
  - genes 673
- epithelial homeostasis 443
  - inflammation-induced alterations 445
  - Notch signaling pathway 444
  - Wnt signaling pathway 443
- epithelium 442
- epitopes 818
  - mapping 820
- EP3 receptor genes 874
- E protein family 342
- EP3-selective agonist 662
- Epstein-Barr virus (EBV) 34, 194, 324, 595
- eritoran 796, 1320
- erythrocytes 255, 788
- erythrodermic psoriasis 1094
- erythro-myeloid progenitor (EMP) 220
- erythropoiesis 224
- erythropoietin 1321
- esalamine (5-aminosalicylate) 465
- Escherichia coli* 83, 191, 278, 423, 672, 732, 816, 839, 1143, 1353, 1424
  - enterohemorrhagic *Escherichia coli* (EHEC) 706
  - Shiga-toxigenic *E. coli* (STEC) 89
- estrogen
  - decreased production of neutrophil 919
  - increase bone marrow progenitor B cells 919
- eukaryotic cells
  - actomyosin cytoskeleton 87
  - proteases 728
- eukaryotic translation initiation factor 4E-binding protein (4E-BP) 1384
- exocytosis 259, 277
- exogenous opioid (EO) 899
- exogenous pyrogen 862, 866, 868, 869
- exopeptidases 727
- exotoxins 278
- experimental autoimmune encephalomyelitis (EAE) 186, 492, 660
- experimental fever in rats, schematic illustration 867
- expressed sequence tag (EST) 628
- extracellular matrix 1525
  - proteins 663



- extracellular signal-regulated protein  
kinase (ERK) 179, 1065, 1205
- extracellular vesicles 1151
- f**
- factor-inhibiting HIF (FIH) 134  
hydroxylates asparagyl residues 134
- familial Hibernian fever (FHF) 265
- familial Mediterranean fever (FMF) 264
- FAS-associated death domain-containing  
protein (FADD) 180, 529
- Fas receptor 533
- fatal autoimmunity 1378
- fat cells  
anti-inflammatory cytokine 506  
fat distribution 1226
- fatigue 861
- fatty acids 1232  
nitrated fatty acids (NO<sub>2</sub>FA) 705  
omega-3 polyunsaturated 1452  
saturated 1233  
short-chain fatty acid (SCFA) 1004,  
1380  
unsaturated 1287
- febrigenic signals 871
- febrile response 861
- Fenton mechanism 713
- fever 861  
beneficial or harmful 876  
clinical aspects 875  
defined 862  
experimentally induced 866  
inducing agent 862  
inflammation 3  
physiological and neuroanatomical  
considerations 862  
of unknown origin 1567
- fibrin degradation products  
(FDP) 425, 845
- fibrin formation 836, 844
- fibrinogen 420, 836, 846, 1349
- fibrinolysis 1549
- fibrinolytic pathways, during  
inflammation 837
- fibrinolytic proteases 739
- fibrin-rich inflammatory matrix  
PTX3-dependent promotion 1356
- fibroblast 675, 1526  
derived extracellular matrix  
proteins 1528  
growth factor 467, 657  
like synoviocytes 1109  
transdifferentiate into  
myofibroblasts 1527
- fibrocytes 5
- fibrogenic growth factors 1527
- fibronectin 1349
- fibrosarcoma, MCA-induced 1394
- fibrosis 675, 1189
- ficolins 786
- flagellin 28, 1588
- flavin adenine dinucleotide (FAD) 703
- flavin mononucleotide (FMN) 703
- flaviviridae, 5'-triphosphate ssRNA 34
- flightless I homolog (Fliih) 1431
- Fluarix influenza vaccine 156
- fluid resuscitation 795
- fluorescence optical imaging (FOI) 1580
- focal adhesion kinase (FAK) 468
- Foerster resonance energy transfer  
(FRET) 502
- follicle-associated epithelium (FAE) 640  
cells 640
- follicular dendritic cell (FDC) 792
- follicular Th (T<sub>fh</sub>) cells 1069
- Fonsecaea pedrosoi* 195
- fontolizumab 352
- food allergy 374, 377
- Food and Drug Administration  
(FDA) 21, 1211, 1677
- Forkhead box family (Foxo)  
proteins 1188  
phosphorylation 1383
- FoxC2 transcription factor 468
- Foxp3 expression 1390  
Foxp3-deficient mice 1387  
Foxp3-driven diphtheria toxin  
receptor 1378  
Foxp3-driven T<sub>REG</sub> phenotype 1378  
Foxp3<sup>DTR</sup> knock-in mice 1393  
Foxp3<sup>DTR</sup> transgenic models 1379  
Foxp3 essential mechanisms 1379  
FOXP3 gene 1011  
Foxp3 genetic deficiency 1060

- Foxp<sup>3+</sup> T<sub>REGS</sub> 1378  
     control of immunity to self-tissues 1391  
*Francisella tularensis* 194  
 free fatty acid (FFA) 1205, 1206  
 free radicals 696  
     induced damage 696  
     mediated injury 715  
     production, mitochondrion, role of 699  
 Friend retrovirus (FV)  
     infection 1396  
 functional  
     abnormalities 464  
     capillaries 1235  
     imaging, to monitor disease activity 1578  
 fungal infections 1397  
     *C. albicans* 1427  
*Fusobacterium nucleatum* 317
- g**
- gamma amino butyric acid (GABA) 865, 1256  
     GABAergic neurons 655  
 gamma/delta T-cell activation 492  
 gammaglobulin, hypergammaglobulinemia 578  
 gasotransmitters 702  
 gastrointestinal  
     function 485  
     surgery 1543  
     tract 438, 439, 1672  
 GATA-binding protein 3 (GATA-3) 342  
     deficient T<sub>REGS</sub> 1387  
     transcription factor 395  
 GC. *see* glucocorticoid (GC)  
 GDP-GTP exchange factor (GEF) 634  
 gene expression 232  
     profile 439  
     score 1553  
 gene loci associated with susceptibility to  
     rheumatoid arthritis 1340  
     systemic lupus erythematosus 1339  
     ulcerative colitis 1337  
 gene markers 916  
 gene profiling 136  
 genetically modified organism (GMO) 1675  
 genetic engineering 1663  
 genetic susceptibility  
     for acute inflammatory conditions 1331  
     general considerations 1335  
     meta-analysis 1334  
     to homogeneous study populations 1331  
     patients with same predisposing condition 1333  
     patients with same underlying infection 1331  
 genetic variant rs1059703 of IRAK-1, X chromosome 1334  
 genome-wide association studies (GWAS) 661, 1067, 1142, 1257, 1330  
 genomic, inflammatory activation 872  
 genomic loci, with autoimmune diseases 1067  
 geranyl geranyl pyrophosphate (GGPP) 1588  
 GH. *see* growth hormone (GH)  
 ghrelin 925  
 glia-derived neurotrophic factor (GDNF) 1258  
 glimepiride 1212  
 glomerular basement membrane (GBM) 800  
 glomerular filtration  
     barrier 1302, 1303  
     of proteins 799  
     rate 1302  
 glomerular injury  
     complement-mediated 800  
 glomerular mesangial cells 802  
 glomerular sclerosis 802  
 glomerulonephritis 264, 995  
 glomerulosclerosis 799  
 glucocorticoid (GC) 11, 869, 917, 1472  
     adversely affect NK cell activity 918  
     genomic effect of 1471  
     glucocorticoid receptor 1470  
     historical perspective 1467

- induced leucine zipper 1430, 1473
- induced tumor necrosis factor
  - receptor 1385
- mechanism of action 1471, 1472
- nongenomic effect of 1473
- overview 1467
- pharmacokinetics 1470
- pharmacological effects 1474
  - adaptive immunity 1474
  - immunomodulation 1474
  - innate immunity 1474
  - other effects 1475
- proinflammatory cytokine production
  - suppression 1489
- receptor antagonist RU486 1430
- therapeutic use of 1475
  - adrenal insufficiency 1477
  - allergy and asthma 1476
  - infectious diseases 1477
  - miscellaneous 1477
  - preventing graft rejection 1477
  - principles 1475
  - renal diseases 1476
  - rheumatic disorders 1476
- upregulate Th2-induced
  - production 918
- glucose
  - D-glucose 22
  - metabolism 1320
- glucose-6-phosphate
  - dehydrogenase 917
- glucose 1 transporter (GLUT1) 982
- glucotoxicity 1232
- glutamate 1493
- glutamatergic neurotransmission 767
- glutathione 711
  - peroxidase 1186
- glycans 36
- glycemia, hyperglycemia 714, 1232, 1233, 1239
- glycerophospholipid metabolic
  - pathway 674
- glycinergic synaptic transmission 655
- glycolipids 30
- glycolysis 956, 982
  - aerobic 1383
  - enzymes 1383
  - metabolism 130
- glycoproteins 182, 440, 462, 533, 536, 788, 1353
  - glycoprotein A repetitions
    - predominant (GARP) 1015
  - glycoprotein-130 receptor 1546
- glycosphingolipid (GSL) 30
- O-glycosylated serine 440
- glycosylphosphatidylinositol (GPI) 24, 35
  - glycolipid 35
  - linked protein 1549
- glycyrrhizic acid 60
- goblet cells 439, 440
  - synthesize 439
- Goodpasture disease 995
- gouty inflammation, acute 263
- GPR. *see* G protein-coupled receptor (GPR)
- G protein-coupled inwardly rectifying K<sup>+</sup> (GIRK) channels 896
- G protein-coupled receptor (GPR)
  - GPR120 deficiency 1288
  - Gpr18 gene 1456
  - P2Y<sub>2</sub> receptor 957
- G protein-coupled receptor kinases (GRKs) 635
- G protein-coupled receptors (GPCRs) 619, 651, 874, 1212, 1287, 1450
  - LGR5 438
  - for prostaglandin D<sub>2</sub> 639
- G-protein-dependent cAMP-protein kinase A (PKA)-mediated signaling 1497
- G proteins 633, 789
  - antagonist 1368
  - coupling 790
  - inhibitors 579
- graft-vs.-host disease (GvHD) 1378
- graft vs. host rejection 530
- granule-mediated cytotoxicity 315
- granulocyte macrophage colony-stimulating factor (GM-CSF) 38, 109, 220, 751, 1429

- granulocyte-monocyte colony-stimulating factor (G-CSF) 150, 592, 594
- granulocytes 1498
- granulomatosis 264
- granzyme B 787, 1552  
mediated killing 1378
- GroES (HSP10) molecules 816
- growth factor-independent 1 342
- growth factor receptor-bound protein 2 (GRB2) 1065
- growth hormone (GH) 921  
lymphocytes 922  
macrophages 921  
NK cell activity 922
- GTPase-activating protein (GAP) 635
- GTPase RhoA-dependent cytoskeletal derangements 1595
- GTPase signaling 1595
- guanine-nucleotide exchange factor (GEF) 1666
- guanine triphosphate deoxynucleotide (CpG) 31
- gut  
associated lymphoid tissue (GLAT) 324  
epithelial cells 996  
inflammation, chronic 460  
injury 59  
microbiome 1238  
guttate psoriasis 1094
- h**
- Haber–Weiss reaction 713
- Haemophilus influenzae* 957, 1179
- HapMap 3 project 1142
- hapten 2,4,6-trinitrochlorobenzene 283
- haptotaxis 257
- Harpagophytus procambius* 1673
- health assessment questionnaire-disability index (HAQ-DI) 555
- healthy obese phenotype 1227
- heart disease 499
- heat shock element (HSE) 814
- heat shock factor (HSF) 814  
monomeric nature of 814
- heat shock proteins (HSPs) 30, 61, 813, 821, 824, 956  
anti-inflammatory protective effects of 820  
biological function of 813  
chaperone functions of 816  
in chronic inflammatory diseases 824  
coinducer 823  
endogenous upregulation 823  
families in mammals and typical microbial homologues. 814  
HSP60 818  
molecule 816, 820  
mycobacterial 818  
HSP70  
chaperone 817  
peptide B29 823  
as prominent peptide donor for MHCII ligandome 817  
protective effect of 820  
T-cell cross-reactivity 819  
HSPH (HSP110) molecules 817  
HSP90 inhibitors 61  
immunology of 817  
as inflammatory mediators 821  
peptides 822, 824  
dendritic cell (DC) 824  
prokaryotic, immunodominance of 817  
self-HSP, cross-reactivity with 818  
specific CD4+ T cells 825
- heat shock response 815  
molecular basis of 814  
triggers for 815
- Helicobacter pylori* 28, 178, 957  
infected gastric tumor 659
- Heligmosomoides polygyrus* 1391  
mouse infection model 1399
- helminth  
immunity 372  
infections 345
- helper T cell 395, 1058
- hemagglutinins 317, 323, 1353
- hematological tumors 642
- hematopoiesis 1546
- hematopoietic stem cell (HSC) 593

- heme oxygenase-1 65  
 hemodynamic management 1301  
 $\beta$ -hemolysin 83  
 hemolytic purpura 801  
 hemolytic uremic syndrome  
     (HUS) 800, 801  
 hemopexin 65  
 hemophagocytic  
     lymphohistiocytosis 497  
*Hemophilus influenzae* 1353  
 hemorrhagic shock 1317  
 hemostasis 1212  
 hemostatic systems 425  
 hen egg white lysozyme (HEL) 1056  
 heparan monomers 1588  
 heparan sulfate 631  
 heparin 277  
     chitosan complexes 282  
     enhances DNA-I-dependent  
         chromatin degradation 1077  
     induced thrombocytopenia 424  
 hepatic  
     CD49a<sup>+</sup> NK cells 319  
     encephalopathy 1495  
     iNKT cells 1492  
     stellate cell 1206  
 hepatitis A virus (HAV) 144  
 hepatitis B virus (HBV) 144, 324  
     vaccine 157  
 hepatitis C virus (HCV) 33, 1069  
 hepatocyte growth factor (HGF) 467,  
     1176  
     activator 467  
 hepatocytes 1227  
 herd immunity 143  
 herpes simplex virus (HSV)  
     glycoproteins of 34  
 Herpesviridae 322  
 hexokinases 982  
 HIF. *see* hypoxia-inducible factor (HIF)  
 high-density lipoprotein (HDL)  
     cholesterol 1233  
 high endothelial venule (HEV) 637,  
     677  
 high-fat diet (HFD) 1201  
 high flux electron transfer  
     pathways 699  
 high mobility group box-1  
     (HMGB-1) 31, 821, 999,  
     1062, 1153, 1518, 1591  
 high molecular weight B cell growth  
     factor (HMW-BCGF) 597  
 high-performance liquid chromatography  
     (HPLC) 1675  
 high-throughput screening (HTS) 1676  
 histamine 283, 375  
 histocompatibility 60 (H60) family of  
     proteins 318  
 histone 796, 842  
     acetylation 1431  
     acetyltransferase (HAT) 1472  
     deacetylases (HDACs) 823, 1472  
     extracellular 1590  
     H3K9 histone methyltransferase  
         G9a 1431  
 H5N1 infection 1260  
 H1N1 nucleoprotein antigen 148  
 H7N9 strains 1354  
 Hodgkin's cells 533  
 homeostasis 184, 344, 395, 538, 927,  
     972, 1142, 1520  
     chemokines 627, 628, 1072  
     molecular and cellular events 816  
     protection 971  
 homodimers 180  
 hormone-GR complex 1472  
 horror autotoxicus 1377  
 horseshoe crab (*Limulus polyphemus*)  
     hemolymph of 23  
 host cell motility, toxins affecting 87  
 host-environment interfaces 273  
 host-pathogen  
     interactions 956  
     systems 81  
 host proteases  
     functions, in inflammation 731  
         antigen presentation, and  
             processing 735  
         antimicrobial functions 732  
         coagulation 739  
         complement system  
             activation 741  
         fibrinolysis 739  
         immunoglobulin cleavage 734

- host proteases (*Continued*)
  - inflammatory mediator
    - processing 732
  - junction molecule
    - degradation 733
  - matrix remodeling 736
  - mucus 734
  - receptor activation 736
  - surfactant protein cleavage 734
- identified in inflammation and 729
  - and inhibitors, origin and
    - distribution 727
  - inflammatory cells 728
  - resident cells 728
- mechanisms of action of 731
- house dust mite (HDM) 790
- HSF. *see* heat shock factor (HSF)
- HSPs. *see* heat shock proteins (HSPs)
- human adipose tissue 1228
- human alpha-defensin (HD)
  - HD-5 446
  - HD-6 expression 446
- human blood monocytes 503
- human CD161<sup>+</sup> ILC1 subset 317
- human chemokines 620
  - receptors 623
- human chromosome 6 532
- human endothelial cells (HUVEC) 109
- human genome sequencing 816
- human herpesvirus 5 (HH5) 322
- human immunodeficiency virus
  - (HIV) 34, 324
  - type 1 1549
- human leukocyte antigens
  - (HLA) 1148
  - locus 1055
- human maternal cells 1055
- human neutrophil elastase (HNE) 1185
- human papillomavirus (HPV) 144
  - vaccine 145
- human polymorphisms 191
- human rhinovirus (HRV) 999
- humoral immunity 639, 792, 1120
- hyaluronan 65, 1153
- 3-hydroxy-kynurenine 773
- hydrogen peroxide 700, 701
- hydrogen sulfide 706, 707, 1319
- N*-hydroxy-L-arginine 703
- 18-hydroxyeicosapentaenoic acid
  - (18-HEPE) 1451
- hydroxyl ions 701
- 3-hydroxy, 3-methyl glutaryl coenzyme A
  - (HMG-CoA) 1588
- 15-hydroxyprostaglandin dehydrogenase
  - (15-PGDH) 1453
- 11  $\beta$ -hydroxysteroid
  - dehydrogenase 1470
- hymenoptera venoms 111
- hyperagggregability 464
- hyperalgesia 654, 676, 861
- hyperdynamic sepsis 1307
- hyperoxia 1317
- hyperresponsiveness 559
- hypersensitivity reactions
  - type II 995
  - type III 995
  - type IV 995, 996
- hyperthermia 106
- hypomethylated CpG sequences 62
- hypoperfusion 1317
- hypothalamic-pituitary-adrenal
  - (HPA) 1486, 1487
  - axis 654, 917, 1469
- hypothermia 861, 877
- hypothyroidism 916
- hypoxia 129, 1227
  - acute vs. chronic hypoxia 136
  - and antigen presentation 953
  - causes of 130
  - chemotaxis in 951
  - include erythropoiesis 129
  - and innate immune cell
    - survival 950
  - molecular sensor signaling 131
  - nuclear factor  $\kappa$ B 135
  - oxygen sensing 130
  - phagocytosis in 952
  - physiological response to 949
  - pulmonary vasoconstriction 1319
  - in regulating innate immune cell
    - function 949
  - role in bacterial killing 952
  - secretory function in 952
  - tissue 263

- hypoxia-inducible factor (HIF) 133,  
922, 1314  
HIF-1 $\alpha$  981  
  phosphorylation 134  
HIF-1 acetylation 134  
HIF-1 $\alpha$ /HIF-1 $\beta$  dimer 133  
target genes 134
- i**
- IBD. *see* inflammatory bowel disease (IBD)
- idiopathic pulmonary fibrosis  
(IPF) 675
- IFN. *see* interferon (IFN)
- Ig. *see* immunoglobulin (Ig)
- ignorant conventional T cells  
(Tconv) 298
- IkappaB kinase beta (IKK- $\beta$ ) 1230  
deletion 490
- IL. *see* interleukin (IL)
- ILC. *see* innate lymphoid cell (ILC)
- imaging  
  modalities, comparison between  
    different 1569  
  of myocardial inflammation, imaging  
    of 1577  
  of systemic infections 1575
- imiquimod 155
- immune  
  activation 1549  
  adherence clearance 788  
  cell activation 790  
  cell death, subversion of 958  
  cell recognition, pathogen avoidance  
    of 957  
  cell trafficking 788, 789  
    neural regulation 1496  
  deficient nonobese diabetic mice 61  
  inflammation  
    Th17 expansion, role of 661  
  network, type I 328  
  reconstitution inflammatory  
    syndrome 1596  
  response 1031  
    to infection 322  
  responsive gene 1 (Irg-1) 955  
  stimulating complexes  
    (ISCOMs) 144, 148  
  system 818  
    aberrant activation 1070  
    defined 19
- immune tolerance 1054  
  APC-presenting autoantigen,  
    tolerogenic signals of 1061  
  B-cell tolerance 1057  
  bystander activation 1068  
  central tolerance 1056  
  costimulation activation 1068  
  dead cell clearance defects 1068  
  environmental factors 1067  
  immune privilege sites 1062  
  induced Tregs (iTregs) 1061  
  infection/tissue injury 1067  
  molecular mimicry  
    by adjuvants 1067  
    by antigens 1067  
  natural Tregs (nTregs) 1061  
  peripheral tolerance 1058  
  regulatory T cells 1059  
  self-antigen, modification of 1068  
  T-cell anergy 1059  
  T-cell tolerance 1056
- immunization 818, 1265
- immunodeficiencies  
  mice 460  
  in phagocytes 1143
- immunodominant  
  antigens 820  
  proteins 820
- immunodulatory cytokines 281
- immunodysregulation,  
  polyendocrinopathy,  
  enteropathy, X-linked  
  (IPEX) 1392
- immunogenic nucleic acids 60
- immunoglobulin (Ig) 222, 225, 317,  
457, 589, 734  
  CAM family members PECAM-1/  
  CD31 469  
  gene 1056  
  immunoglobulin G (IgG) 422  
  immunoglobulin A (IgA)  
    nephropathy 1069  
    producing plasma cells 640  
  immunoglobulin E (IgE)

- immunoglobulin (Ig) (*Continued*)
  - antibodies 275
  - dependent mast cell responses 366
  - FcεRI activation 279
  - mediated hypersensitivity 995
  - production 591, 996
- immunoglobulin G (IgG)
  - antibodies 786
  - immune complexes 796
- immunoglobulin M (IgM)
  - antibodies 786
- immunological disorders 861
- immunology, definition of 57
- immunometabolic
  - coupling 982
  - imbalance 980
- immunometabolism
  - and acute inflammation 981
  - and chronic inflammation 980
- immunomodulation 1597, 820
- immunopathology 1394
- immunoproteasome 735
- immunoreactivity 818
- immunoreceptor tyrosine-based
  - activation motif (ITAM) 317
- immunoregulation 219, 223, 228
- immunostimulants 530
  - ligands 143, 157
  - properties 57
  - regimens 1596
- immunosuppression 226, 229, 232, 664
  - drug 677
  - protocols 1147
- immunotherapy 824
- Incomplete Freund's adjuvant (IFA) 146
  - oil-in-water emulsions 147
- indocyanine green (ICG)-enhanced
  - fluorescence optical imaging (FOI) 1580
- indoleamine-2,3-dioxygenase (IDO) 773, 1112
- indomethacin-treated wild-type mice 655
- induced Tregs (iTregs) 1061
- inducible T cell costimulator (ICOS) 1386
  - ICOS-ICOSL interactions 348
- infection 8, 341
  - agents 795
  - suspected systemic, and local infections 1574
- inflammasome 192, 742, 792, 796, 1184, 1205, 1237, 1283
  - activation 138
  - mitochondrial and cytoplasmic activities 137
  - pathway 145
  - toxins modulating 82
- inflammation 1, 6, 8, 319, 322, 341, 342, 457, 626, 785, 787, 874, 915, 1147, 1199, 1210, 1226, 1313, 1372, 1545, 1567, 1673
- inflammatory bowel disease (IBD) 348, 373, 445, 457, 533, 549, 659, 734, 818, 1116, 1136, 1486, 1488, 1674
  - anti-TNF-α 558
  - central angiogenic stimulus 466
  - delivers
    - microvascular permeability 468
- immunoblockade experiments in
  - animal models 464
- lymphatic transport function 468
- patients 460
  - morbidity and mortality 463
- inflammatory disorders 437, 739, 785, 815
  - C5a, C5aRs and C3aR, role in 795
  - chronic, genetic predisposition for 727, 792, 1336
  - psoriasis vulgaris and psoriatic arthritis 1338
  - rheumatoid arthritis (RA) 1340
  - systemic lupus erythematosus (SLE) 1339
- models 666
  - HSP in 819
- inflammatory mediators 107, 654, 817, 959, 962
  - cytokines and chemokines 961
  - microvesicles 965
  - oxidants 959
- inflammatory signals, peripheral 874



- inflammatory skin diseases 1092, 1098  
alopecia areata 1099  
atopic dermatitis 1098
- influenza A 317
- inhibitor of DNA binding 2 (ID2)  
expression 342
- inhibitory receptors 317
- innate immunity 175, 425, 479,  
713, 785, 790, 876, 947,  
997, 1315  
adaptive immunity, cross-talk  
between 1112  
 $\gamma$   $\delta$  T cells 1113  
antigen presentation 958  
complement, role in 790  
damage-associated molecular  
patterns activate 956  
function  
impact of host-pathogen  
interactions 956  
microenvironmental factors in  
regulating 948  
helper 2 cells 344  
IL-1 superfamily 479  
immune cells 785, 790, 996, 1203  
activators of 791  
in acute inflammation 794  
innate defense regulator 1591  
manipulating phagocytosis 958  
metabolic intermediates in  
augmenting 955  
recruitment, preventing 957  
responses 102, 273, 956, 1147, 1148  
inflammation triggered by 1664  
lipid mediators in 964  
system activation 1315
- innate lymphoid cell (ILC) 315, 341,  
591, 996, 997, 1002, 1094, 1111  
ILC2 and ILC3, therapeutic  
harnessing of 351
- inositol triphosphate (IP3) 1666
- insulin 1230  
hyperinsulinaemia 1229  
receptor 1230  
signaling 1226, 1230  
substrate (IRS) 1205, 1207, 1230,  
1231  
resistance 1199, 1207, 1225, 1230,  
1231, 1233, 1239  
adipocytes 1232
- insulin receptor substrate (IRS)  
mRNA expression 1233  
proteins 1230, 1231
- integrin (ITG) 1315  
activation 1518  
VLA4 627
- intensive care unit (ICU) 1331
- intercellular adhesion molecule  
(ICAM)-1) 1203
- interferon (IFN) 82, 1092  
cytokines 178  
IFN- $\gamma$  341, 735, 916, 1425  
prevented colitis induction 1388  
production 28  
receptor, IFNGR1 knockout 599,  
600  
transcription factor 1097
- interferon (IFN)  $\alpha$  and  $\beta$  1285, 1286  
IFNAR1 targeted deletion 600  
receptor-dependent secondary gene  
expression 1076  
regulatory factor 179, 231, 232, 366,  
975  
signature 188
- interleukin (IL) 834  
IL-1 21, 1363  
family member 7 501  
functional role 508  
receptor antagonist 480, 658, 1523  
receptor family member ST2 498  
receptor type I 479, 482  
subfamily, of receptors 480  
superfamily 479–483
- IL-1 $\alpha$  1518  
cell sources 484  
deficient mice 486  
dual-function cytokine 484  
endothelial cells 485  
as growth factor 485  
in healthy/disease cells 484  
historical background 483  
membrane 485, 486  
mouse cDNA cloning 483  
nuclear translocation 484

- interleukin (IL) (*Continued*)
  - precursor 484, 485
  - systemic effects in humans 483
- IL-1 $\beta$  492, 654, 732, 862
  - deficient mice 490, 491
  - historical background 486
  - immunoblockade 465
  - LPS-induced synthesis 489
  - NLRP3 inflammasome-dependent processing 488
  - noncaspase-1 processing 489
  - precursor 489–491
  - production by human platelets 424
  - production, regulation 487
  - P2X7, inflammasome activation 489
  - regulatory regions 487
  - systemic effects 487
  - transcription/translation/synthesis 487
- IL-1R
  - associated kinase 1430
  - family 1365
- IL-1R8 481
  - deficient mice, primary macrophages and DCs 502
- IL-1Ra anakinra, anti-inflammatory potency 1365. See also anakinra
- IL-1RI, deficient mice 495
- IL-2 149, 590, 1058
  - anti-inflammatory properties of 1366
  - derived from T cells 347
- IL-3
  - receptor  $\alpha$  chain 593
- IL-4 395, 590
  - promote generation of Th2 cells 365
  - secreted by Th2 cells 366
- IL-6 103, 573, 822, 1366, 1519, 1542, 1546
  - biological activity and signaling system of 573
  - blockade therapy 579, 580
  - blockade treatment strategy 580
  - clinical application of members of 578, 579
  - dependent signaling 1366
  - gene 1366
  - IL6-receptor (IL-6R) 1257, 1285
    - complex associated with gp130 574
  - inhibitors, clinical application of members 578
  - and its family of cytokines 573
  - new members 575
  - original members of 575
  - and receptor components 575, 576
  - receptor deletion 872
  - receptor system, nonsignaling and signaling receptor components 574
  - redundant and nonredundant functions 578
  - soluble forms of nonsignaling and signaling receptors 577
- IL-7 591, 1203
  - $\alpha$  chain 591
  - receptor 317, 342
- IL-8 89, 103
- IL-9 591
  - receptor  $\alpha$  chain (CD129) 591
  - signaling 345
  - transgenic airway mouse model 375
- IL-10 1366
  - anti-inflammatory properties of 1367
  - subfamily receptors 600, 601
- IL-11 575
- IL-12 492, 594, 1285
  - cytokine family 1367
  - IL-12p40 deficiency 1285
  - stimulate the generation of Th1 cells 365
  - subfamily cytokines 594, 595
- IL-15 150, 592
  - essential for NK cell homeostasis 327
- IL-17
  - blockers, therapeutic in CD 553
  - clinical findings 556
  - cytokine family 549, 557

- cytokines, cell sources of 549, 552
- cytokines, in normal and inflamed intestine, production and role 551
- cytokines in psoriasis 553
- and its activity, secretion of 404
- neutralization, therapeutic efficacy of 555
- in pathogenesis of autoimmune diseases 492
- receptor 492, 550
- receptor A subunit 1098
- in rheumatoid arthritis 552, 556
- IL-17A
  - glycoprotein 549
  - in psoriatic arthritis 555
- IL-17B, IL-17C, and IL-17D
  - in immune-inflammatory diseases, role of 557
- IL-18 492, 1284
  - binding protein 490, 493, 495
  - blocking 493
  - concept of 496
  - coreceptor 1284
  - deficiency 495, 1284
  - genes 491
  - in heart disease 494
  - hemophagocytic syndromes 497
  - human, natural neutralization 497
  - IFN $\gamma$  492
  - and inflammation 493
  - precursor by caspase-1 491
  - proinflammatory properties 493
  - as protective cytokine 495
  - receptor (IL-18R) 494, 1284
  - signal transduction 491
- IL-18 binding protein (BP) 494
  - discovery 495
  - gene 1365
  - in immune responses 496
  - regulation 496
- IL-18R
  - deficiency 1284
- IL-18R $\alpha$  502
  - chain 1364
  - extracellular IgG-like domains 481
- IL-19 601
- IL-20 602
- IL-21 592
  - receptor-deficient animals 592
- IL-22 602
  - signals 602
- IL-23 595
  - and/or IL-1 $\beta$  stimulation 344
  - receptor 550
- IL-24 602
- IL-25
  - mediated promoting effects on Th2 cell responses 558
  - production by commensal bacteria 558
  - production constitutive in human and mouse liver 558
  - significantly ameliorates renal function and 558
- IL-25R, expressing lamina propria dendritic cells 558
- IL-26 603
- IL-27 595, 1367
- IL-33 499
  - binding 499
  - discovery 498
  - heterozygous mice expressing 500
  - in human disease 500
  - nuclear function 499
  - precursor 498, 499
  - receptor 1389
  - shares 499
- IL-35 596, 1367
  - producing regulatory T cells 1368
- IL-36
  - background 500
  - receptor antagonist (IL-36Ra) 480
  - role of 500
- IL-37 502, 1364
  - aging 506
  - background 501
  - binding studies 502
  - crystallization 503
  - disease models 504
  - experimental colitis 505
  - genes 491

- interleukin (IL) (*Continued*)
  - in human disease 507
  - ischemic and damage models 505
  - metabolic syndrome 505
  - mRNA levels 506
  - precursor 489, 507
  - processing and release 503
  - production 503
  - protein 503, 508
  - recombinant effects 504
  - requirement for Smad3 507
  - signaling complex 501
  - spinal cord injury 505
  - tg deficient, in IL-1R8 502
  - tg mice 502, 505, 507
  - translocation of 506
- IL-37b
  - full-length precursor cDNA of 504
- IL-38 508
  - dose-response suppression 508
  - IL-1 family member 10, functional role of 508
- ILCs
  - in adult tissues, maintenance of 344
  - development, model for 343
  - ILC2 (innate lymphoid cells)
    - activation 347
    - in acute and chronic inflammation 345
    - and chronic inflammation 347
    - deficiency 347
    - expansion 345
    - human, expresses 344
    - in infection and chronic inflammation 346
    - and metabolic disorders 348
    - and parasitic infection 345
    - and viral infection 347
  - ILC3
    - activated by IL-1 $\beta$  and IL-23 344
    - in acute and chronic inflammation 348
    - chronic inflammation, and cancer 350
    - in clinic, targeting 351
      - and commensal or pathogenic bacteria 348
      - during gut infection and inflammation 349
      - lineage 342
      - vs. B/T development 342
- International Association for the Study of Pain (IASP) 891
- intestinal
  - epithelial cells 440
  - immune system 640
  - inflammation 447
  - injury 1317
  - lumen 447
- intracellular adhesion molecule 1(ICAM-1) 1474
  - expression 463
- intracellular nucleoside triphosphate 63
- intracellular nucleotide oligomerization domain (NOD)-like receptors 1315
- intracellular signal transduction 597
- intracranial aneurysm (IA) 658
- intraepithelial lymphocyte (IEL) 592, 641
- intraperitoneal thyroxine 916
- invariant natural killer T cells (iNK T cells) 1524
- irritable bowel syndrome 1674
- ischemia-reperfusion 1152, 1155, 1313, 1317, 1318
  - antioxidant therapy 1319
  - clinical studies 1317
  - injury 715, 803, 1313
  - pathophysiology 1314
  - phenomenon 1317
  - therapeutic gases 1319
  - therapeutic perspectives 1318
  - tissue injuries 1316
  - upregulate the MHC antigens expression 1150
- ischemia tolerance, improving 1320
- ischemic conditioning 1318
- ischemic stroke 877
- isoforms Rho-A 88

- itaconate 955  
Ixekizumab 408, 555, 557
- j**  
Janus kinase (JAK) 366  
  activation 1065  
  enzymes 1671  
  inhibitory peptide 1211  
  JAK3 signal transduction  
    capability 590  
  signal transducer and activator of  
    transcription (STAT)  
    pathways 589, 592, 1671  
    signal cascade 1430  
junctional adhesion molecule  
  (JAM) 257, 443, 469
- k**  
Kaposi sarcoma-associated  
  herpesvirus 575  
Kc-derived PGE<sub>2</sub> 873  
kelch-like ECH-associated protein  
  (Keap1) 712  
keratinocytes 400, 554, 1092, 1094  
  activating mechanism 602  
  trigger innate 1096  
ketotifen 283  
kidney  
  injury 1078  
  ischemia 1365  
  normal, anatomy and  
    physiology 1302  
  tubules and peritubular capillaries  
    inflammatory effects on 1304  
killer immunoglobulin-like receptors  
  (KIR) 183, 318  
  molecules 319  
killer lectin-like receptor subfamily G  
  member 1-positive  
  (KLRG1) 1386  
kinin-kallikrein system 740  
*Klebsiella pneumoniae* 191, 732, 1353  
Krebs cycle 954, 955  
Kupffer cells 5, 224, 789, 870, 873,  
  1206, 1207  
kynurenine amino transferase  
  (KAT) 774  
  pathway, in schizophrenia 774  
kynurenine mono-oxygenase  
  (KMO) 774  
  pathway in major depressive  
    disorders 774
- l**  
laboratory of genetics and physiology 2  
  (LGP2) 188  
lactoferrin 259  
lamina propria (LP) 1387  
Langerhans cells 154, 641, 949, 1096  
  in psoriasis  
    immunopathogenesis 1096  
langerin 1092  
lateral parabrachial nucleus (LPB) 865  
*LCE* genes 1338  
Lebrikizumab (anti-IL-13) 352  
*Legionella pneumophila* 191  
*Leishmania* infection 149  
  *Leishmania donovani* 182  
  *Leishmania* lipophosphoglycan 36  
  models 1398  
leptin 867, 869, 923, 1200, 1207, 1233  
  CRP interactions 1207  
  deficiency 923  
  lymphocytes 923  
  macrophages 923  
  neutrophils 923  
  NK cell 923  
  receptor 923  
lesional IL-17-producing T cells 1094  
lethal bacterial infections 1424  
lethal factor (LF) 84  
leucine-rich protein 66  
leucine-rich repeat (LRR) 176  
leukemia inhibitory factor (LIF) 575  
leukocyte reprogramming 26, 1423, 1431  
  anti-inflammatory cytokines 1429  
  clinical relevance 1427  
  cross-tolerance 1425  
  endotoxin tolerance 1423, 1426  
    affect anti-infectious  
      immunity 1427  
  epigenetic 1431  
  glucocorticoids 1430  
  macrophage plasticity 1432

- leukocyte reprogramming (*Continued*)
  - microRNAs (miRNA) 1431
  - regulatory signaling downstream
    - TLR 1430
  - reversal 1429
- leukocytes 102, 258, 425, 619, 626, 1154, 1494, 1521
  - adhesion 263
    - endogenous regulators of 462
    - endothelial cell adhesion 462
    - extravasation, multistep model of 627
    - HMGB1 promotes 60
    - recruitment, during IBD 463
    - reprogramming (*See* leukocyte reprogramming)
    - rolling (E-selectin) 462
    - trafficking 1496
  - leukotaxine 8
  - leukotrienes (LTs) 103, 277, 279, 374, 619, 965
    - inflammation, role in 664
    - leukotriene A<sub>4</sub> (LTA<sub>4</sub>) 653
    - leukotriene B<sub>4</sub> (LTB<sub>4</sub>) 653, 923, 965, 1212, 1449
      - hydrolase 1452
      - receptor 664
    - leukotriene C<sub>4</sub> (LTC<sub>4</sub>) 653
    - leukotriene D<sub>4</sub> (LTD<sub>4</sub>) 352
    - receptors 664, 669
  - Lewy body-like neuronal inclusions 1261
  - Lgr5*-positive stem cells 439, 444
    - daughter cells 438
  - ligand-protein interactions 1676
  - ligand-receptor relationships 628, 629
  - limulus amebocytes 419
    - limulus amebocyte lysate 23
    - mammalian platelets, comparison 420
  - α2-3-linked N-glycolylneuraminic acid 89
  - lipid A relates to bacteria 22
  - lipids
    - hyperlipidemia 1212, 1239
    - lipid peroxyl radical (LOO<sup>•</sup>) 701
    - lipid phosphate phosphatase (LPP) 674
    - mediators 964, 1372, 1449
      - biosynthesis, degradation, and receptors of 652
      - synthesis 1385
    - lipocalin-2 expression 1428
    - lipopeptide adjuvanted vaccine (LYMERix™) 151
    - lipopeptides adjuvant 151
    - lipopolysaccharide (LPS) 19, 151, 177, 221, 422, 771, 862, 916, 1257, 1351, 1424, 1426, 1588
      - activated macrophages 955
      - binding protein 1546
      - fever model 870
      - induced PD models 1260
      - induced TNF 26
      - in vitro* capacity of 1425
      - LPS binding protein (LBP) 24, 1333, 1426
        - nonresponding strain 1425
        - stimulation in human blood monocytes 487
        - tolerance 1331
        - tolerized macrophages 1428
    - lipoproteins 177
      - lipoprotein receptor-related protein (LRP) 443
    - liposomes 148
      - nano/microparticles 148
    - lipoteichoic acid (LTA) 27, 1369
    - lipotoxicity 1232, 1284
    - lipoxins 228, 348, 1449, 1451
      - biosynthesis 1450
      - lipoxin A<sub>4</sub> (LXA<sub>4</sub>) 352, 965, 1449
      - lipoxin B<sub>4</sub> (LXA<sub>4</sub>) 965
    - lipoxygenase (LOX)
      - enzymes 1449, 1451
      - expression 1209
      - 5-lipoxygenase 1454, 1672
      - pathway 791
    - Listeria monocytogenes* 82, 325, 706, 1397, 1398
    - listeriolysin O (LLO) 82
    - liver failure 837
    - liver fibrosis 675
    - liver injury 64, 1364

- liver kinase B1 (LKB1) 1384  
     deficient T cells 1385  
 LN. *see* lymph node (LN)  
 locus coeruleus (LC) 1487, 1490  
 low-density lipoprotein (LDL) 715, 1279  
     cholesterol 1233  
     LDL-LDL receptor complex 1468  
     receptor (LDLR) 1280  
 low-grade inflammation, in  
     human 1210  
 LOX. *see* lipoxygenase (LOX)  
*Loxosceles* spp.  
     envenomation 109  
     venoms 108, 109  
 LPA. *see* lysophosphatidic acid (LPA)  
 LPS. *see* lipopolysaccharide (LPS)  
 LTs. *see* leukotrienes (LTs)  
 lung dendritic cells  
     activated by epithelial cells 296  
 lung injury 504, 1356  
 lung lesions 795  
 lupus nephritis 802, 1073  
     in kidney 1076  
         aberrant tissue repair 1078  
         chemokines recruit leukocytes 1077  
         immune complex  
             glomerulonephritis 1076  
         toll-like receptor activation 1077  
     morphology of 802  
 Ly49 complex 318  
 lymphangiogenesis 230, 457, 465  
 lymphatic system 1154  
 lymph endothelial cells 663  
 lymph node (LN) 324, 344, 1072, 1112, 1151, 1154  
     resident 289  
 lymphocytes 626, 918  
     activating factor 11, 483  
     activation gene 3 819, 1163  
     with antigen 1058  
     circulation  
         S1P/LPA, role of 676  
     trafficking 425  
 lymphocytic choriomeningitis virus (LCMV) 1395  
 lymphoid lineage 593  
      $\alpha$ -lymphoid precursors 342  
     lymphoid progenitor cells 591  
         and expression 341  
     lymphoid tissue inducer (LTi) cells 343, 344  
     lymphopoiesis 636  
     lymphotoxin 365  
         alpha/beta (LT $\alpha$ / $\beta$ ) 344  
     lysine 27  
         N-terminus 504  
     lysolecithin. *see* lysophosphatidylcholine (LPC)  
     lysophosphatidic acid (LPA) 667  
         LPA<sub>6</sub> 674  
         LPA-LPA<sub>1</sub> signaling 675  
         production  
             by ATX 672  
             by phosphatidic acid-selective phospholipase A1 (PA-PLA1 $\alpha$ ) 673  
         receptors for 668, 670  
         S1P, pathophysiological roles 674  
         structure 668  
         synthetic, degrading, and action of 672  
         synthetic pathways and enzymes 671  
     lysophosphatidylcholine (LPC) 667, 676  
     lysophosphatidylethanolamine (LPE) 667  
     lysophosphatidylglycerol (LPG) 667  
     lysophosphatidylinositol (LPI) 667  
     lysophospholipase D (lysoPLD) 671  
     lysophospholipid 667  
     lysosomal hydrolases 182  
     lysosomes 635, 817
- m**  
 Mac1. *see* macrophages, antigen complex 1  
 macrophages 219, 224, 289, 327, 328, 347, 366, 401, 788, 916, 917, 947, 949, 956, 1000, 1150, 1151, 1227, 1228, 1233, 1283, 1351, 1498, 1525  
     activation syndrome 497, 1598

- macrophages (*Continued*)
- antigen complex 1 228, 1263
    - activation 803
  - chemotactic protein-1 665, 1282
  - colony-stimulating factor 594, 834
  - dendritic cell precursor 219
  - immunoregulatory properties 224
  - infiltration 658
  - inflammatory protein 8
  - M1-type 1000
  - in obese adipose tissue 1201
  - phenotypes 222
  - polarization 232
  - tissue macrophage (TM) 228, 949
- macrophages chemotactic protein-1 (MCP-1) 658
- macropinocytosis 789
- macrovascular disease 1234
- magnetic resonance imaging 1567, 1573
- major basic protein 1002
- major histocompatibility complex (MHC) 590, 735, 1106, 1148, 1596, 1666
- class I, antigens 1149
    - expression of 1150
    - inhibitory receptors 317
  - class II antigens 822, 1149
    - expression of 1150
    - like "Y box 532
  - MHC-I-deficient environment 319
  - MHC-I receptors 319
  - molecules 1149, 1151
- malaria 148, 426, 1398
- induced thrombocytopenia 426
- mammalian nitrogen oxide cycle 704
- mammalian platelets 419
- mammalian target of rapamycin (mTOR) 954, 1188, 1205
- pathway 1672
- mammalian tissue mast cells 102
- manganese superoxide dismutase (Mn-SOD) expression 715
- mannose-binding lectin (MBL) 786, 1155, 1349
- lectin 2 1333
- mannose receptor (MR) 182
- mannosyl fatty acids 185
- MAPK. *see* mitogen-activated protein kinase (MAPK)
- maraviroc 642
- markers, of coagulation activation 848
- mass spectrometry (MS) 1675
- mast cells 273, 662, 788, 790, 1001, 1204, 1496
- activation (*see* mast cell activation)
  - in adaptive immunity 279
    - antigen presentation 280
    - DCs and effector T cells to sites of infection, recruitment of 280
    - dendritic cells and T cells to draining lymph nodes, recruitment of 280
    - as effectors of adaptive immunity 279
  - biology of 273
  - degranulating (MCD) 111, 667, 995
  - degranulating peptide (MCDP) 111
  - enhancement of immunity by boosting 281
    - activators as novel vaccine adjuvants 281
    - synthetic granules 281
  - during immune responses, potentially detrimental roles 282
  - negative modulation of immunity by 283
  - overactivation 282
  - in immune surveillance 275
    - activation by endogenous danger signals 276
    - degranulation and secretory responses to pathogens 277
    - direct recognition of pathogens 275
    - indirect recognition of pathogens 276
    - strategic peripheral location 275
  - in innate immunity 278
    - direct bactericidal activity 278
    - induction of immune cell trafficking to sites of infection 279



- resistance to exo- and endotoxins 278
- release prestored granules upon activation 274
- mastocytosis 375
- matrigel sponge 663
- matrix metalloproteinases (MMP) 228, 469, 803, 1109
  - MMP 3 555
  - MMP-1 expression 666
- matrix-synthetic myofibroblasts 1526
- MBL-associated serine proteases (MASP) 786
- mechanistic target of rapamycin complex (mTORC)
  - mTORC2 complexes 1384
  - phosphorylation 1384
  - mTORC1, T-cell biology 1381
- medial preoptic area (MPO) 865
- median preoptic nucleus (MnPO) 865
- medicinal herbs 1670
- medullary thymic epithelial cell (mTEC) 1057, 1380
- melanocortin receptor (MSH) 927
  - MC1 and MC3 927
- melanocortins 927
  - lymphocytes 927
  - macrophages 927
  - neutrophils 927
  - NK cells 927
- melanocyte-stimulating hormone (MSH) 927
- melanoma differentiation-associated gene 5 188
- melanoma differentiation-associated protein 5 35, 62
- melatonin 711
- melittin 112
- membrane attack complex (MAC) 787, 1316
- membrane-bound precursor (tmTNF $\alpha$ ) 530
- membrane cofactor protein (MCP) 793
- membrane-type PGE synthase (mPGES) 654
- membranous glomerulonephritis (MGN) 799
  - idiopathic 800
- memory/effector T cells 289, 639
- memory inflation 323
- mepolizumab (anti-IL-5) 352
- meprin- $\beta$  734
- mercaptopyruvate sulfurtransferase (MST) 707
- Merkel cells 1091
- mesangial cells 1305
- mesenchymal stem cell (MSC) 505, 1596
- mesenteric lymph nodes 348, 1017
- metabolic disorders 1674
- metabolic stress 322
- metabolism, and nutrient availability 953
- metallo-beta-lactamase (MBL) 1587
- metalloproteinases (MMP) 264, 402, 530, 631, 733, 1201
- methacholine 375
- methionine 707
  - enkephalin peptides 348
- methotrexate therapy 556
- N*-methyl-D aspartate (NMDA) receptor 773
- methylene blue 870
- methylglyoxal (MGO) 1239
- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 1262
  - MPP<sup>+</sup> neurotoxicity 1264
- MF59 adjuvanted flu vaccine 147
- MHC. *see* major histocompatibility complex (MHC)
- mice deficient
  - in caspase-1 490
  - in NLRP6 494, 495
- microarray technology 1676
- microbe/pathogen-associated molecular patterns (MAMPs/PAMPs) 137
- microbial invasion 1349
- microbial pathogens 175
- microbial pattern recognition 997

- microbial proteases 753
  - effects on
    - barrier function 744
    - complement proteins 746
    - cytokine/chemokine production 746
    - vascular permeability 745
  - and inflammation 742
- microbial recognition 1353
- microbial virulence factors 82
- microbicidal proteins 422
- microbiota
  - in allergic inflammation 1003
  - induced gut inflammation 177
- micrococcus prodigiosus 8
- microfold cells (M cells) 640
- microglia cells 530, 539, 1256, 1257
  - activation 776
  - Mac1 receptor
    - and NADPH oxidase, coupling of 1264
- microgliosis 1264
- microorganism/microbe associated
  - molecular pattern (MAMP) 19
- microphages 6
- microRNAs (miRNAs) 234, 1142, 1371
- microsomal prostaglandin E synthase-1 (mPGES-1) 868
- microvascular dysfunction 1235, 1314
- microvascular endothelium 1154
- microvascular function 1239
- microvascularization 1315
- microvascular thrombus formation
  - in vascular beds 464
- migration inhibitory factor (MIF) 11, 1063, 1551
- milk fat globulin (MFG) 225
- misshapen-Nck interacting kinase-related kinase (MINK) 1065
- mitochondria-derived peptides 957
- mitochondrial-associated membrane (MAM) 188
- mitochondrial DNA (mtDNA) 58, 62, 1384
- mitochondrial dysfunction 1317
- mitochondrial enzyme complex
  - cytochrome c oxidase 129
- mitochondrial growth stimulant
  - activity 1596
- mitochondrial oxygen
  - controlled reduction to water 700
  - sensing, cytochrome oxidase 131
- mitochondrial respiratory chain 699
- mitochondrial ROS (mROS) 960
- mitochondrial superoxide dismutase (mtSOD) 132
- mitochondrial transition pore (mPTP) 1314
- mitogen-activated protein (MAP) 635, 789
- mitogen-activated protein kinase (MAPK) 134, 152, 550
  - signaling pathways 86, 1667, 1671
  - signaling, toxins modulating 85
  - synergy between ET/LT 86
- modified vaccinia virus Ankara (MVA) 1396
- molecular mechanism 219
- molecular trafficking 699
- monoclonal antibody 1098
  - SAP antibody 1355
- monocyte chemotactic protein (MCP) 1228
  - MCP-1 89, 109, 1203
- monocytes/macrophage 219, 233, 401, 530, 626, 628, 631, 949, 999, 1000
  - activation and polarization 221
  - CD14<sup>+</sup> cells 1200
  - functions 222–230
    - antigen presentation 226
    - cytokine production and inflammation 223
    - immunoregulation 228
    - migration 227
    - phagocytosis 224
    - vascular functions 229
- molecular pathways and mechanisms
  - regulating response 230–235
  - epigenetic regulation 232
  - micro-RNAs 234
  - signaling pathways 230

- nonclassical 632
- origin and differentiation 219
- recruitment 956
- monogenic autoimmune
  - diseases 1066
- Mono-Mac-6 cells 1429
- mononuclear cells 657
  - specific chemokines 1522
- monophosphoryl lipid A (MPLA) 21, 144, 145, 153
- monosodium urate (MSU)
  - crystals 63
- mouse chemokines 620
- mouse cytomegalovirus (MCMV) 319
  - infection, acute 323
- mouse mast cell protease 6
  - (mMCP6) 279
- mouse MHV coronavirus
  - infection 1395
- mouse T-cell line 483
- mRNA transcription 599
- MUC2* gene 446
- mucin (MUC) 734
  - domains 440
  - granules, exocytosis 440
  - proteins 439
- Muckle-Wells syndrome 482
- mucosa-associated lymphoid tissue (MALT) 1061
- mucosal-associated invariant T (MAIT) 1070
- mucosal immunity 344, 636
  - CCR6<sup>+</sup> and NCR<sup>+</sup> ILC3 344
  - and chemokines 640
- mucosal ischemia 1592
- multicomponent receptor systems 573
- multidrug-resistant (MDR) 1584
- multidrug-resistant protein 1 (MRP1) 653
- multiple cellular functions 1673
- multiple sclerosis (MS) 659, 661, 793, 819, 1264, 1392, 1671, 1674
- multiplexed molecular markers 1552
- multiplicity of infection (MOI) 959
- multitarget drug discovery 1662
- muramyl dipeptide (MDP) 191, 1427
- muramyl tripeptide (MTP) 1427
- murine alveolar macrophages 1429
- murine chromosome 17 532
- murine endosomal TLR7 32
- murine Ptx3 genes 1351
- musculoskeletal disorders 1567
- mycobacterial antigens 820
- mycobacterial lipomannan 25
- Mycobacterium avium* subspecies
  - paratuberculosis* 1143
- Mycobacterium bovis* BCG
  - infection 1397
- Mycobacterium leprae* 1397
- Mycobacterium tuberculosis* 181, 325, 492, 503, 706, 819, 958, 1586
  - HSP71 31
- Mycoplasma fermentans* 27
- MyD88. *see* myeloid differentiation
  - primary response-88 (MyD88)
- myeloid cells 193, 329, 593, 788, 1367
  - degranulation in 788
  - dendritic cells 1096
  - expressing 6-sulfo-LacNAc 1096
- myeloid-derived suppressor cell (MDSC) 1163
- myeloid differentiation primary response-88 (MyD88) 1364, 1430
  - adapter molecule 1430
  - associated pathway 59
  - binding 501
  - dependent pathway 1426
  - dependent receptor 83
  - dependent signaling 179, 1371
    - by IL-1R8 for TLR signaling 501
  - dimerization 1590
  - homodimeric formation 1590
  - in inflammation 105
  - knockout mice 105
  - protein 1590
- myeloid inhibitory C-type lectin (MICL) 185
- myeloperoxidase (MPO) 705, 1201
- myocardial infarction (MI) 715, 793, 1313
- myofibroblasts 675

- myosin light chain kinase  
(MLCK) 459
- Myrmecia* genus ant venom 111
- n**
- N*-acetylcysteine 1320
- N*-acetyl-glucosamine (N-AcGlc) 27, 28
- N*-deacetylase-*N*-sulfotransferase 1 (Ndst1) 1286
- N*-acetylmuramic acid (N-AcMur) 28
- N*-acetylmuramyl-*L*-alanyl-*D*-isoglutamine 28
- N*-acetyl-*p*-benzoquinoneimine (NAPQI) 712
- $\alpha$ 7nAChR agonists 1503
- NADPH oxidase (NOX) 696, 700, 916, 917, 1186, 1264, 1265
- activations 1265, 1314
- enzyme isoforms 700
- therapeutic targeting 1265
- NAD<sup>+</sup>-sensing protein with lysine deacetylase activity 983
- nanotransducing regulatory elements 709
- nasal-associated lymphoid tissue (NALT) 281
- natural antibodies 818
- natural cellular process 714
- natural cytotoxicity receptors 317
- NKp46 (in mice and man) and NKp44 (in man) 344
- natural killer (NK) 30, 183, 227, 315–319, 322–324, 341, 400, 492, 530, 534, 550, 592, 916, 971, 1003, 1111, 1315
- activation 318, 322, 920
- activating and inhibitory signals regulate 321
- in men 919
- CD27<sup>+</sup>CD11b<sup>-</sup> 320
- education/licensing 318
- gene complex-associated CLRs 183–187
- activation receptors 183
- CLR signaling 186
- inhibitory receptors 185
- and group 1 ILCs, in inflammation/infection 322
- cells and other viral infections 324
- effector functions of 320
- evidence for distinct subsets of 319
- Influenza virus 323
- Listeria monocytogenes* 325
- memory 326
- mouse cytomegalovirus 322
- mycobacteria 325
- as partners in type 1 network 327
- Salmonella typhi* 324
- of human 316
- maturation 319
- receptor CD161 344
- T cell 600, 1003, 1070
- transcript 4 597
- natural LPS ligands 25
- natural products 1661–1663, 1674
- derived bioactive compounds 1668
- use of nanotechnology 1677
- navamepent 1453
- necrotic cells 224, 1155, 1517
- Neisseria meningitidis* 916, 1353
- neoplastic growth 861
- neovascularization 1118
- net filtration pressure (NFP) 1302
- neural pathways 874
- neural transmission 874
- neuraminidase 323
- neurodegeneration 1255–1257, 1264, 1265
- disease-modifying therapy 1265
- inflammation-related models of 1259
- novel anti-inflammatory therapy for 1265
- progressive, inflammatory mechanisms of 1262
- neuroendocrine 915
- neurohumoral immunomodulatory pathway 1489
- neuroimmune
- communicatome 1486–1488
- bioelectronic medicine 1503

- brain function in peripheral inflammation 1494
- immune cells 1499
  - trafficking, neural regulation of 1496
- inflammation, neural sensing of 1493
- inflammation resolution, neural regulation of 1498
- nervous system 1492, 1496
- neurogenic inflammation 1493
- neurotransmitters, in neuronal circuits controlling inflammation 1497
- peripheral inflammation focusing on cholinergic mechanisms 1501
- pharmacological anti-inflammatory approaches 1503
- points of interaction 1492
- translational exploration 1502
- neuroinflammation 1255–1257, 1488, 1493, 1496
  - beneficial effects of 1258
  - detrimental effects of 1258
  - dysregulated 1262
  - modulation of 1265
  - reflex 1372
- neuronal apoptosis inhibitory protein (NAIP) 28
- neuronal nitric oxide synthase (nNOS) 703
- neuronal thermoregulatory circuitries 864
- neurons 866, 1257
  - derived self-compounds and microglial Mac1 bridges microgliosis and chronic neurodegeneration, interactions 1263
  - injured, form a self-perpetuating vicious cycle driving neurodegeneration progression 1262
  - median preoptic nucleus (MnPO) 866
- neuropathic pain 676
- neuropeptide Y 927, 928, 1493
- neurotensin 278
- neurotransmitters 130, 862
- neurotrophic factors 1256
- neutralizing antibodies 145, 795, 1098
- neutrophil elastase (NE) 265, 734
  - elastase 2 1552
- neutrophil extracellular trap (NET) 85, 103, 175, 423, 425, 732, 796, 842, 843, 1111, 1427, 1522, 1590
- neutrophil gelatinase-associated lipocalin (NGAL) 1524
- neutrophils 104, 261, 278, 279, 325, 327, 328, 401, 425, 536, 626, 628, 732, 788, 790, 876, 915, 916, 947, 949, 956, 966, 980, 1097, 1154, 1315, 1524, 1543
  - adhesion/migration 255–258
    - to endothelial wall 256
  - traffic 255
  - transendothelial 257
- apoptosis 261
- characteristics 253
- cytokine synthesis 260–261
  - IL1 and IL-1 receptor antagonist 260
  - IL-8 as model of chemokines 261
  - modulation of cytokine expression, and production by neutrophils 261
  - TNF- $\alpha$  260
- derived cathepsins 634
- functions 962
- glucocorticoids (GCs) increased blood level 918
- hematopoiesis 254
- in pathology 262–265
  - autoimmunity against neutrophil components 264
  - bacterial infection 263
  - crystal-induced inflammation 263
  - cystic fibrosis, neutrophil-mediated tissue damage 265
  - cytokine-induced inflammation, rheumatoid arthritis 263

- neutrophils (*Continued*)
- genetic disorders regulations, hereditary periodic fever syndromes 264
  - tissue injury-induced
    - inflammation, ischemia-reperfusion injury 263
  - phagocytosis and
    - degranulation 258–260
    - degranulation 259
    - phagocytosis 258
  - sequestration 263
  - sources of oxidants in 960
  - transepithelial migration 258
- New Delhi metallo-beta lactamase (NDM-10) 1587
- next-generation sequencing (NXS) 1330
- NF. *see* nuclear factor (NF)
- NFκB RelB-dependent silent heterochromatin formation 983
- NF-κB. *see* nuclear factor kappa B (NF-κB)
- nicotinamide adenine dinucleotide 700
- Nippostrongylus brasiliensis* 345, 558
- nitric oxide (NO) 37, 459, 462, 463, 697, 702, 923, 1230, 1428, 1672
- deficiency 460
  - enzymatic and nonenzymatic production 703
  - H<sub>2</sub>S cross-talk 708
  - indirect anti-inflammatory effects 706
  - interferon gamma (IFN-γ)-induced production 706
  - mRNA expression 845
  - reactive intermediate (RNI)
    - peroxynitrites 104
  - synthases (NOS) 697, 822, 868, 1314, 1544, 1672
  - cNOS, defined 703
    - inducible nitric oxide synthase (iNOS) 703, 705, 917, 959, 1203, 1432, 1672, 1673
- nitrogen dioxide (\*NO<sub>2</sub>) 697, 704
- nitrotyrosine (NO<sub>2</sub>Tyr) 705
- NK. *see* natural killer (NK)
- NKG2D ligands 318
- NKp46 activation 317, 323
- NLR. *see* NOD-like receptor (NLR)
- nociception 112, 891, 893
- NOD-like receptor (NLR) 28, 137, 144, 188–193, 225, 441, 997, 1423, 1488, 1518
- classification and signaling pathway 190
  - family pyrin domain containing 3 (NLRP3) 58, 1237
  - NLRC4 missence mutation Thr337Ser 483
  - NLRP3 inflammasome 63, 66, 83, 788, 798, 1237, 1239, 1283, 1284
    - activation by dopamine 1501
  - NLRP3 knockout cells 138
  - NLR proteins (NLRPs) 138, 192
  - NOD1 and NOD2 191
    - signaling 192
    - pyrin-domain containing 3 33
- nonalcoholic fatty liver disease 1199
- noncanonical inflammasome pathway 82
- noncanonical NFκB signaling 660
- nonclassical MHC-I molecules 318
- non-ELR CXC chemokines 631
- non-Hodgkin lymphoma 637
- nonlymphoid tissue-resident T<sub>REGS</sub> 1389
- non-MHC-I-based self-receptors 319
- non-NK hematopoietic cell types 315
- nonpermissive promoters 233
- nonshivering thermogenesis (NST) 863
- nonsteroidal anti-inflammatory drug (NSAID) 654, 877, 1257
- nonthyroidal illness (NIST) syndrome 916
- norepinephrine (NA) 862
  - preoptic area, role of 874
- norepinephrine (NE) 1488, 1489
- normal skin
  - immune organ 1091
  - inflammation by polarized T-helper cell subsets 1092

- Notch intracellular domain (NICD) 445
- Notch signaling 444
- Notch transcription factor RBPj 445
- novel antibacterial agents 1586
- novel sulfido lipid mediator  
conjugates, in tissue regeneration 1457
- NOX. *see* NADPH oxidase (NOX)
- noxious stimulus 1517
- nuclear erythroid 2-related factor (Nrf2) 712
- nuclear factor (NF) 550, 1366  
activated T cells (NFAT) 1162  
interleukin-3 (NFIL3) 342  
kappa B 868  
cascade 1519  
pathway 223, 446, 836  
kappa-light-chain-enhancer 1667
- nuclear factor kappa B (NF-κB)  
activation 58, 462, 466, 920  
inducing kinase (NIK) 192  
signaling 957, 1285  
translocation 1590
- nuclear imaging 1567  
nuclear magnetic resonance (NMR) 1675  
spectroscopy 1553
- nuclear medicine techniques 1574
- nucleosome remodeling 232
- nucleotide-binding domain and leucine-rich repeat pyrin containing protein-3 (NLRP3)  
inflammasome 491
- nucleotide-binding oligomerization domain (NOD) 59, 189  
containing protein 1 (NOD1) 1427  
NOD2 risk haplotypes 1143  
receptors (*See* NOD-like receptor (NLR))
- nucleotide pyrophosphate phosphodiesterase (NPP) 672
- nucleus tractus solitarius (NTS) 873, 1487, 1489, 1490
- nuocytes 344
- nutraceuticals 1212, 1670
- O**
- obesity 499, 505, 1199, 1213, 1226, 1488  
associated inflammation in type 2 diabetes 1236  
associated low-grade inflammation 1226  
associated type 2 diabetes 1229  
induces inflammation in diverse organs 1206  
phenotypes, and therapeutics 1210  
as profibrotic disease 1208
- obstructive sleep apnea (OSA) 136
- occludins 733
- oil-in-water emulsions 144, 147
- oligomerization 188
- oligonucleotide (ODN) 156
- Omics technologies 1552
- oncogenesis 1546
- oncostatin M (OSM) 575
- open canalicular system (OCS) 419
- opioids 875, 901  
peptides 899  
receptors  
plasticity, and signaling pathways 896  
and signaling 896
- opsonins 225, 786, 787, 789–791, 1543  
antibodies 1584  
receptors 225, 789, 791
- orexins  
macrophages 929  
neutrophils 929
- organ function, loss of 3
- organogenesis 219
- organ-specific inflammation 1161
- organ transplantation 1147, 1313
- organum vasculosum laminae terminalis (OVLT) 871
- orphan type I cytokines 596  
G-CSF signals 598
- orthomyxoviridae  
5'-Triphosphate ssRNA 34
- orthopoxviruses 324
- osteoarthritis (OA) 1674
- osteoclasts 221, 1115  
regulation 598
- osteomyelitis 1567

- osteopontin 918, 1203, 1525
  - outer membrane protein A (OmPA) 27
    - deficient mutants 27
  - outer-surface protein A (OspA) 151
  - OVA. *see* ovalbumin (OVA)
  - ovalbumin (OVA) 292
    - induced allergic asthma model 662
  - oxidative damage 701
    - DNA damage 710
  - oxidative injury 916
  - oxidative phosphorylation (OXPHOS) 954, 1383
    - oxidative metabolism 915
  - oxidative stress 695, 697, 698, 961, 1186, 1212
    - antioxidant gene expression, role of 712
    - biomarkers of 701
  - oxidized LDL (oxLDL) 1283
    - derived cholesterol 1291
  - OX40 ligand 280
  - OX40L-OX40 536
  - oxygen
    - delivery 1318
    - diffuses 131
    - hypoxia, cascade demonstrating levels of 950
    - sensing 130
      - transcription factors 133
- p**
- pain
    - basic concepts of 891
      - excitatory mechanisms 892
      - inhibitory mechanisms 895
    - clinical concepts of 899
      - analgesic drugs 900
      - biopsychosocial concept and multidisciplinary management 900
    - translation of basic research into clinical applications 902
  - paleopathology 1
  - Pam2Cys lipopeptide 151
  - PAMP. *see* pathogen-associated molecular pattern (PAMP)
  - pandemrix 147
  - paneth cells 438, 439, 441, 446
  - pannexin-1 489
  - panton-valentine leucocidin (PVL) 959
  - paracoccidoides brasiliensis 1353
  - paramyxoviridae
    - 5'-Triphosphate ssRNA 34
  - parasitic infections 1398
  - paraventricular hypothalamus (PVH) 655
  - paraventricular nucleus (PVN) 1487, 1489
  - Parkinson's disease 1489
  - paroxysmal nocturnal hemoglobinuria (PNH) 803
  - PASI 75 scores 555
  - passive ligand 257
  - pathogen, agents targeting 1585
  - pathogen-associated microbial proteases 743
  - pathogen-associated molecular pattern (PAMP) 19, 57, 105, 175, 223, 275, 654, 791, 821, 862, 868, 956, 974, 997, 1032, 1152, 1351, 1369, 1423, 1486, 1541, 1583, 1585, 1587
    - agents targeting host responses 1589
    - bacterial
      - DNA 31
      - fimbriae 30
      - flagellin 28
      - glycogolipids 30
      - heat shock proteins 30, 822
      - lipoproteins 26
      - lipoteichoic acid 27
      - peptidoglycan 28
      - RNA 32
    - CD28 costimulatory signal peptide inhibitors 1598
    - epithelial membrane barriers 1592
    - extracellular/intracellular signaling inhibitors 1590
    - fungal 36
    - hemoperfusion systems 1584
    - high mobility group box 1 (HMGB1) 1592



- histone inhibitors 1590
- immune reconstitution
  - strategies 1596
- immunomodulators 1595
- interleukin-1 receptor antagonist (IL-1ra) 1598
- mesenchymal stem cells 1596
- mitochondrial sparing agents 1596
- parasitic infection 35
- proresolving agents 1592
- receptor for advanced glycation end products (RAGE)
  - inhibitors 1591
- recombinant gelsolin 1591
- statins 1588
- vascular endothelium in acute inflammatory states 1594
- viral PAMPs 33
- pathogens 956
  - clearance 785
  - initiated innate immune responses 58
  - opsonization 787
  - removal 785
- patrolling monocytes 219
- pattern recognition molecule (PRM) 1349
- pattern recognition receptor (PRR) 19, 58, 82, 175, 223, 275, 441, 996, 1237, 1281, 1369, 1423, 1485, 1541, 1588
  - C-type lectin-like receptor 175
  - distribution 176
  - nucleotide-binding oligomerization domain (NOD)-like receptor 175
  - retinoic acid-inducible gene-1-like (RIG-1) receptor 175
  - sensing necrotic cells 59
  - toll-like receptor (TLR) 175
- PCT. *see* procalcitonin (PCT)
- PDE4 inhibitor 1190
- pellino-3b deactivates IRAK-1 1431
- pentose phosphate pathway (PPP) 982
- pentraxin 3 (PTX3) 1352, 1354, 1542–1544
  - coated surfaces 1355
  - deficiency 1356
  - deficient mice, in skin and liver damage 1356
  - deficient remodeling cells 1356
  - general scenario 1349
  - protein 1352
  - resistant mutants 1354
- peptide hormones 442
- peptidoglycan (PGN) 19, 25, 28, 191, 192, 959
  - chemical structure 29
  - peptidoglycan-associated lipoprotein (PAL) 27
  - peptidoglycan recognition protein (PGRP) 30
- peptidyl-arginin deiminase 1108
- peptidyl isomerases (PPIases) 27
- periodontitis 1233, 1447
- peripheral lymphoid organs 677
- peripheral nerves 1491
  - injury 676
- peripheral tolerance 1054
- perivascular macrophages 918
- peroxisome proliferative activated receptor (PPAR) 982, 1227, 1390
  - $\gamma$  (PPAR $\gamma$ ) 106, 231, 446, 668, 705, 954, 1205, 1236
  - activation 1237
- peroxynitrite (ONOO<sup>-</sup>) 697, 704, 705, 713, 1265
- persistent critical illness (PCI) 1592, 1593
- Peyer's patches 344, 348, 551, 637, 640
  - of carvacrol-treated animals 823
- PGF<sub>2 $\alpha$</sub> -FP signaling 663
- PGN. *see* peptidoglycan (PGN)
- PGs. *See* prostaglandins (PGs)
- phagocytes 5, 6, 262
  - microglia 1256
  - professional 224
- phagocytosed bacteria 791
- phagocytosis 4, 223–225, 366, 419, 789, 802, 916, 1155, 1307, 1544
  - induced cell death 958

- phagosomes 192, 224, 259
- PHD. *see* prolyl hydroxylase dehydrogenase (PHD)
- phenol-water extraction 26
- Phoneutria nigriventer* venom
  - causes paralysis 110
- phorbol-12-myristate-13-acetate (PMA) 1426
- phosphatase and tensin homolog (PTEN)
  - activation 1385
  - catalyze 1382
- phosphatidic acid (PA) 671
- phosphatidic acid-selective phospholipase A<sub>1</sub> (PA-PLA<sub>1</sub>α) 673
- phosphatidylinositol 3-kinase (PI3K) 1230, 1231, 1371, 1672
  - activation 789
  - Akt/mTOR pathway 1385, 1672
  - pathway 1382
  - phosphoinositide 3-kinase γ (PI3 kinase γ) 635
- phosphatidylinositol-(3,4,5)-triphosphate (PIP3) 1381
- phosphoinositide-dependent kinase 1 (PDK1) 1381
- phospholipase C dependent 488
- phospholipases 100, 257
  - phospholipase A<sub>2</sub> (PLA<sub>2</sub>) 651, 671, 869
  - on membrane
    - phospholipids 1672
  - phospholipase C 635
  - phospholipase D 671
- phospholipid cardiolipin 299
- phospholipomannan 37
- phosphorylated insulin receptor 1230
- phosphorylation 195, 259, 366, 813, 1205, 1431
- phosphorylcholine (PC) 1353
- phytohemagglutinin (PHA) 483
- pioglitazone 1237
- pituitary gland (PitG) 1488
- pituitary hormones 920
  - arginine vasopressin (AVP) 920
  - lymphocytes, and macrophages 920
  - NK cells 920
- placental growth factor (PIGF) 466
- plasmacytoid dendritic cell (pDC) 156, 599, 1092, 1112
  - derived IFN-α 1096
- plasmacytomas 1366
- plasma kallikrein-kinin system 741
- plasma proteins 457
- plasminogen activator inhibitor-1 (PAI-1)
  - expression in endothelial cells 845
- plasminogen-plasmin system 844
- Plasmodium cynomolgi* 1428
- Plasmodium falciparum* 426
- plasmodium infection 1398
- platelets 836
  - activating factor 619
  - bacteria, interactions 422
  - bacterial endotoxin (LPS)
    - adherent 422
  - consumption 834
  - human platelets 420, 424
    - and inflammatory disorders 425
  - inflammatory processes 421
  - integrins 424
  - leukocyte aggregates 423, 424
  - leukocyte interactions 423
  - Limulus polyphemus* 419
  - membrane glycoprotein (GP)
    - Ibα 423
  - microparticle 421, 425
  - nonhemostatic components 421
  - platelet-activating factor (PAF) 106
  - platelet-derived growth factor (PDGF) 467
  - platelet endothelial cell adhesion molecule-1 (PECAM-1) 257, 466, 1203
  - recruitment 463
  - role in immune responses 425
  - signaling 426
  - toll-like receptors, expression
    - of 422
  - white blood cells, interactions 423
- PLCγ cleaves phosphatidylinositol bisphosphate (PIP2) 1666
- pleckstrin-homology domains 1381

- pleiotropy 573  
*Pneumocystis carinii* 182  
 pneumolysin 83  
 podocytes 799, 800  
 polarization 627  
 poliovirus 178  
 polyangiitis 264  
 polyclonal 1151  
 polyglycolic acid (PGA) 1677  
 polyinosinic-polycytidylic acid  
     (poly I:C) 60, 152, 1426  
 polyketides 1676  
 polymorphic protein-1 (PMP-1) 422  
 polymorphisms 177, 185, 1120  
 polymorphonuclear (PMN)  
     infiltration 1452  
     leukocyte (PML) 423, 791, 1447  
 poly lactic-*co*-glycolic acid  
     (PLGA) 1677  
 polysaccharidic moiety 22  
 polyubiquitination 192  
*Porphyromonas gingivalis* LPS 1426  
 positron emission tomography  
     (PET) 1257, 1568  
 post-translational modifications 789,  
     954  
 power Doppler ultrasound  
     (PDUS) 1580  
 Poxviridae family 324  
 p50p65 NF- $\kappa$ B heterodimer 1431  
 preadipocytes 1205, 1228  
 preepigenetic sensing, and  
     signaling 974  
 preimmunization 819  
 preoptic area (POA) 655, 864  
 presepsin (soluble CD14  
     subtype) 1547  
 p70 ribosomal protein S6 kinase 1  
     (S6K1) 1384  
 primary lymphoid organs, and  
     chemokines 636  
 primary percutaneous coronary  
     intervention (PCI) 1318  
 PRL. *see* prolactin (PRL)  
 proapoptotic signaling 529  
 procalcitonin (PCT) 1542, 1544  
     guided algorithms 1545  
     induction 1544  
     levels 1544  
     production 1544  
     values 1545  
 progesterone  
     reduce NK cell activity 919  
     suppresses antibody production 920  
 programmed cell death protein 1  
     (PD1) 1163  
 proinflammatory  
     cytokines 37, 60, 188, 193, 223, 505,  
         592, 654, 788, 815, 838, 842,  
         920, 1315  
     responses 1498  
     genes 179, 180, 658  
     and immunoregulatory factors 341  
     leukocyte influx 1523  
     mediators 557  
     T cells 1228  
         T helper 17 cells 1367  
 prolactin (PRL) 921  
 proliferation 457  
     signals 592  
 prolyl hydroxylase dehydrogenase  
     (PHD) 134  
     enzymes 1320  
     on HIF 132  
     inhibitors 1320  
 promyelocytic leukemia zinc finger  
     (PLZF) 343  
*Propionibacterium acnes* 491, 1426  
 proprotein convertase subtilisin kexin 9  
     (PCSK9) 1592  
 proresolving lipid mediators, in  
     resolution of acute  
         inflammation 1448  
 prostaglandins (PGs) 102, 229, 348,  
     619, 651, 654, 917, 1449  
     anti-inflammatory actions 663  
     autoimmune and allergic  
         inflammation, role in 659  
     as cytokine amplifiers 657  
     degrading enzyme 664  
     positive feedback loops of  
         inflammation, role in 657  
 prostacyclin (PGI<sub>2</sub>) 459, 463  
     IP pathway 654

- prostaglandins (PGs) (*Continued*)
  - mediated amplification 658
  - prostaglandin E<sub>2</sub> 862, 964
    - CXCL1 pathway 659
    - EP2 signaling 658
    - EP3 signaling 662
    - EP4 signaling 657, 659
    - induced edema formation 654
      - in MnPO, role of 874
  - prostaglandin E synthase 869
  - prostaglandin H<sub>2</sub> 459
  - receptors for 669
  - roles in nervous system 656, 657
  - Th2-mediated allergic inflammation,
    - role in 661
  - Th1/Th17-mediated autoimmune
    - inflammation, role in 660
  - tissue remodeling 663
- prosthetic valve 1567
- protease-activated receptor
  - (PAR) 734, 997, 1595
    - activation on cells, inflammation-
      - related effects of 737
- proteases 732, 736
  - hyperactivity 727
  - inhibitors 729, 1350
  - as targets in inflammatory
    - pathologies 747
      - airways 748
      - gut 747
      - joints 751
      - pancreatitis 752
      - skin 750
      - traumatic brain injury 752
- proteasome 192
- protectin 1452
  - protectin D1 (PD1) 1498
- protective antigen (PA) 84
- protein
  - alterations 813
  - docking, computer algorithms 1676
  - folding 88
  - modifications 814
  - structure 1352
  - synthesis 1385
- proteinases 727
  - proteinase-3 732, 734
  - protein C 1316
    - activation 839
    - pathway 838
    - system 837, 839, 844
  - protein kinases 1666
    - dependent signal transduction 589
    - protein kinase A 655
    - protein kinase C 186, 635, 655, 789,
      - 960, 1230, 1666
      - $\gamma$ -isoform 676
    - protein kinase G 702
  - proteolysis 577, 1549
  - proteolytic
    - activity 727, 733
    - cleavage 787
  - proteomics 100
  - prothrombin time (PT) 834
  - prothrombotic state 837
  - protocadherin (PCDH1) 999
  - protocatechuic acid 1288
  - Protonectarina sylveirae* venoms
    - 112
  - proximity ligation assay (PLA) 502
  - PRR. *see* pattern recognition receptor (PRR)
  - Pseudomonas aeruginosa* 4, 191, 706, 959
  - psoriasis 1092
    - anti-IL-17 therapy in 554
    - area and severity index 554, 1097
    - psoriatic arthritis 555, 1116
    - clinical and histological
      - features 1093
      - molecular features 1092
    - guttate 1094
    - immunopathogenesis 1091
    - lesions 1093
    - plaque 1094
    - pustular 1094
    - skin 1093
      - adaptive immune responses 1096
      - biopsy 1093
      - dendritic cells interplaying with
        - T cells 1096
      - IL-12p40 1097
      - IL-23/TH17 1098
      - inflammation 1094, 1095

- inflammatory molecules for  
     targeted treatment 1097  
 keratinocytes triggering  
     innate 1096  
     neutrophils 1097  
     T cells 1094  
     TNF- $\alpha$  1098  
 skin lesions 1096  
     vulgaris 1091, 1094  
 PTEN. *see* phosphatase and tensin  
     homolog (PTEN)  
 PTX3. *see* pentraxin 3 (PTX3)  
 pulmonary edema, acute 107  
 pulmonary embolism (PE) 464  
 pulmonary fibrosis 347  
 putative proteinase maturation protein  
     A (PpmA) 27  
 putative pyrogens, possible sites of  
     action for 864  
 P2X<sub>7</sub> receptor 957  
     Glu496Ala loss 489  
 pyocyanic bacillus 4  
 pyocyanin 959  
 pyrin domain (PYD) 1370  
 pyrogenic cytokines 868  
 pyrogens 874  
     interfere 864  
     pyrogenic zone 865  
 pyroptosis 138, 195  
 pyrotoxina 4, 21
- q**
- quantitative D-dimer assay 846  
 Quillaia saponins 148
- r**
- RA. *see* rheumatoid arthritis (RA)  
 RAG-complementation analyses 1382  
 Rag-independent innate  
     lymphocytes 316  
 RANK ligand 344, 1110, 1115  
 rapamycin 794  
 Raphe pallidum neurons 655  
 rapid signal transfer 873  
 rapid thermoregulatory responses 864  
 RAS/MAPK pathways 593, 1230  
 RC-529 adjuvanted vaccines 154  
 reactive free radical 710  
 reactive nitrogen species (RNS) 697,  
     702  
     anti-infectious agents, as 705  
     general properties 698  
     metabolism 704  
 reactive oxygen species (ROS) 104,  
     132, 175, 260, 278, 695, 697,  
     700, 791, 815, 916, 1177, 1189,  
     1205, 1258, 1314, 1522  
     biomarkers of 701  
     general properties 698  
     redox interconversion of 708  
 reactive sulfur species (RSS) 706  
     general properties 698  
 receptor 4-1BB 533  
 receptor for advanced glycation  
     end-products (RAGE) 60,  
     1518  
 receptor for hyaluronan-mediated  
     motility (RHAMM) 1154  
 receptor interaction protein (RIP) 180  
 receptor retinoic acid (RA) 341  
 receptor tyrosine kinase signal  
     transduction 465  
 recombinant human APC  
     (rhAPC) 840  
 redox code 697, 698  
     health and disease, use in 713  
     principles 699  
 redox diseases 713  
 redox-related switch-off signal 713  
 regulatory T cells (Treg) 292, 299,  
     366, 395, 407, 505, 640, 819,  
     1094, 1203, 1212, 1377, 1423,  
     1524  
     accumulation 1204  
     adipose tissue 1389  
     canonical genes 1380  
     clinical perspectives 1399  
     in context of infections 1394  
     depletion 1396  
     effector 1386  
     intestinal 1390  
     molecular mechanisms 1380  
     natural Tregs (nTregs) 1060  
     nonlymphoid tissue-resident 1389

- peripheral-induced 1390
  - populations 1388
  - subpopulations 1379
  - subsets 1060
  - suppressor 1377, 1378
  - thymus-derived *vs.* peripherally derived 1379
- rejection, chronic 1159
- renal
  - allografts 1154
  - biopsies, human 800
  - blood flow (RBF) 1302, 1303
  - damage 1320
  - dysfunction 802, 803
  - isografts 1154
  - response to systemic
    - inflammation 1304
    - changes in renal
      - hemodynamics 1307
      - endothelial activation 1304
      - glomerular filtration barrier changes 1305
      - tubular injury 1306
    - transplantation 1320
    - vasodilation 1307
- renin-angiotensin-system (RAS) 1235
  - aldosterone system 915
- reperfusion 263, 1155, 1314
- reprogramming 1428
- resistin 926
  - resistin-like molecule  $\beta$  (RELM $\beta$ ) 345
- resolvin D1 (RvD1)
  - RvD1 1454
- resolvin E1 (RvE1) 1451
  - RvE1 formation 1452
  - RvE1 signals 1452
- respiratory burst 713
- respiratory syncytial virus (RSV) 34
- resveratrol (RES) 1211
- reticulo-endothelial system 5
- retinoic acid-inducible gene-1 (RIG-I) 32, 62
  - receptors 1315, 1541
- retinoid acid-related orphan receptor
  - (ROR) 549
  - alpha 315
    - gamma 397
- retinopathies 230
- reverse cholesterol transport (RCT) 1280
- reverse pharmacology 1662
- rhabdoviridae
  - 5'-Triphosphate ssRNA 34
- rheumatoid arthritis (RA) 65, 263, 496, 530, 578, 659, 792, 918, 1105, 1106, 1392, 1488, 1671, 1674
  - clinical phenotype 1106
  - endothelial cells 1111
  - etiology 1106
  - fibroblast-like synoviocytes 1109
  - inflammatory cells and mediators driving 1109
  - innate immunity and stromal cells 1109
  - innate lymphoid cells 1111
  - monocytes and macrophages 1110
  - neutrophils and mast cells 1111
  - structural changes in
    - cartilage damage and bone erosions 1115
- rhinosinusitis, chronic, associated with nasal polyps 347
- rhodopsin-like family of GPCRs 632
- Rho GTPases family 87
- RIG-I-like receptors (RLRs) 137, 187–188, 997, 1369
  - signaling 188, 189
- rituximab 802
- RNA
  - derived markers 1552
  - ribosomal 1385
- single-stranded (ssRNA) 178
- RNase A-type ribonucleases 66
- RNS. *see* reactive nitrogen species (RNS)
- RORc expression 404
- ROS. *see* reactive oxygen species (ROS)
- Ross River virus 1354
- rostral raphe pallidus nucleus (rRPa) 865
- rostromedullary lateral medulla (RVM) 1487, 1490

- rotational thrombelastography  
(ROTEM) 846
- S**
- S. agalatae* 423
- salivary gland (SVG) 320
- Salmonella enterica* 30, 1354
- Salmonella typhi* 917
- Salmonella typhimurium* 83, 192, 957,  
1353
- Salmonella typhosa* 1423
- salsalate 1211
- SAP. *see* serum amyloid P (SAP)
- sarcoidosis 1576
- scavenger cells 788
- macrophages 788
- monocytes 788
- neutrophils 788
- scavenger receptors 1281
- class A (SR-A) 1280
- sCD40 ligand 466
- schistocytes 800
- Schistosoma mansoni* 36, 420, 1398
- egg 36
- Schwartzman reaction 21
- scorpion *Leiurus quinquestriatus* 106
- scorpion venoms
- inflammation induced 105–107
- inflammatory action, schematic  
  representation of 108
- SEB-induced toxic shock 1590
- secondary lymphoid organ (SLO) 637
- secretory mucin-containing  
  granules 440
- Secukinumab 408, 553–556
- segmented filamentous bacterium  
  (SFB) 551
- selectins (Sel) 1518
- E-selectin 280, 461, 1154
- P-selectin 462, 1154
- dependent reaction 836
- glycoprotein ligand-1  
  (PSGL-1) 256, 957, 1154
- selective PPAR- $\gamma$  modulators  
  (SPPARMs) 1237
- self-induced ligands 184
- self-nucleic acids 178
- seminal experiments 1392
- senescence 1189
- sense perturbations 131
- sensitization 999
- phase 996
- sensory circumventricular organs  
  (sensory Cvos) 871
- sensory neurons 1493
- sepsis 795, 947, 1031, 1331, 1488,  
1542
- acute mortality 1032
- clinical management 1037
- DAMPs 1033
- dendritic cells 1035
- epidemiology 1031
- incidence 1031
- host immune response 1032
- illness concepts updated definitions  
  and clinical criteria  
  limitations of previous  
  definitions 1037
- Sepsis-3 1037, 1038
- immune cell abnormalities in 1034
- induced mortality 177
- lymphocytes 1035
- macrophages 1034
- mechanisms of organ dysfunction  
  in 1037
- metabolic alterations in 1036
- mitochondrial function in 1036
- monocytes 1034
- natural killer cells 1035
- and neutrophils 1034
- pattern recognition receptor 1033
- polymicrobial 795, 798, 803
- transduction of danger signals  
  1033
- Sepsis-related Organ Failure  
  Assessment score (SOFA  
  score) 1038
- septic shock 1038
- serine and threonine kinases 1231
- serine proteases 786, 1316
- serine-rich repeat (Srr) 423
- serine/threonine kinase protein kinase B  
  (PKB/Akt) 1381
- serine/threonine-phosphorylation 1231

- serotonin 1497
  - producing enterochromaffin cells 442
- Serratia marcescens* 8, 21
- serum albumin 711
- serum amyloid A (SAA) 965, 1282
- serum amyloid P (SAP) 1352
  - component 1349
  - deficient mice 1355
  - protomers 1351
- serum sickness 995
- serum therapy 1584
- severe sepsis-induced ADAMTS13
  - deficiency 837
- sex hormones 918
- sexual dimorphism 918
- SH1-containing inositol-5' phosphatase (SHIP-1) 1430
- Shiga toxins (Stxs) 88
- Shigella dysenteriae* 1424
- Shigella* infection 801
- SHIP-deficient mice 1383
- short consensus repeat (SCR) 788
- short-hairpin 1454
- sialic acid 323
  - binding immunoglobulin-like lectin 9 1579
- sickness behaviors 861
  - encompasses fever 1494
- sickness-induced lethargy 657
- signaling chains 589
- signal regulatory protein-alpha (SIRP $\alpha$ ) 225
- signal transducer and activator of transcription (STAT)
  - pathway 366, 963, 1097
- signal transduction 587–589, 596, 600, 634
  - signal transducers 921
  - signal transducing receptor 573
- silent mating-type information
  - regulator-2 (Sir2) 983
- single IgG domain of IL-18BP is similar to IL-1R8 (SIGIRR) 496
- single-nucleotide polymorphism (SNP) 661, 1329, 1331
  - for acute and chronic inflammatory disorders 1342
  - associated with susceptibility to the development of sepsis 1332
  - and functional genomics 1330
  - homozygosity 1339
  - selection of 1331
- single photon-emission computed tomography (SPECT) 1568, 1572
- Singleton-Merten syndrome 188
- siRNA treatment targeting
  - HMGB1 60
- Sirt1 epigenetic-based homeostat for sepsis
  - inflammation treatment 986
- sirtuins 983
  - in inflammation 984
- Sjogren's syndrome 329
- skin
  - associated lymphoid tissue 1091
  - homing immunity 1092
  - homing T cells 1091
  - immunity and chemokines 641
  - inflammation
    - T-helper subtypes 1093
  - keratinocytes 484
- SLE. *see* systemic lupus erythematosus (SLE)
- sleep disturbance 861
- Smad3 protein 507
- $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) 675, 1526
- smooth muscle cell (SMC) 791
- snakebite envenoming constitutes 100
- snake venoms
  - induced edema 101
  - inflammation 99–105
  - proteomics 100
- SOD. *see* superoxide dismutase (SOD)
- soluble decoy TLRs 1371
- soluble egg antigen (SEA) 36
- soluble mediators 370
- soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) 1548
- soluble urokinase-type plasminogen activator receptor (suPAR) 1549
  - levels 1549



- specialized proresolving mediators
  - (SPM) 965, 1448, 1488
  - specific receptors and biological actions 1450, 1457
- sphingosine (Sph) 673
- sphingosine-1-phosphate (S1P) 667
  - receptor 637, 670, 671, 1524
  - structure 668
  - synthetic
    - degrading, and action of 672
    - pathways 673
- sphingosylphosphorylcholine (SPC) 673
- spiders
  - brown 108
  - venoms
    - inflammation induced 107–110
- spinal protein kinases pathways 112
- spleen tyrosine kinase (Syk) 183
- spondyloarthritis 1116
  - adaptive immunity 1119
  - bone remodeling in 1121
  - cells and mediators driving 1117
  - clinical phenotype 1116
  - cross-talk between innate and adaptive immunity 1118
  - dendritic cell (DC) 1119
  - iNKT cell 1119
  - MAIT cells 1119
  - $\gamma\delta$ T cells 1119
  - etiology 1116
  - innate immunity and stromal cells 1117
    - endothelial cells 1118
    - fibroblast-like synoviocytes 1117
    - innate lymphoid cells 1118
    - monocytes and macrophages 1117
    - neutrophils and mast cells 1118
- spondyloarthritis (SpA) 1105
- S100 proteins 1092
- Src homology 2 domain-containing inositol-5-phosphatase (SHIP1) 1382
- Src inhibition 469
- Src-kinase tyrosine phosphorylation 469
- SRR adhesins 423
- Staphylococcus aureus* 83, 326, 422, 732
  - pore-forming toxin 959
- Staphylococcus epidermidis* 31, 486, 1575
- starfish larvae 4
- statin-induced 13-series resolvins 1457
- STAT proteins 366
  - STAT1, activation 596
  - STAT3
    - deficient T<sub>REGS</sub> 1388
    - dependent mechanism 550
    - protein 404
    - signal transduction 595
- sterile
  - liver 1356
- steroids
  - hormones 917
  - natural/synthetic, relative potencies of 1471
- sterol regulatory element-binding protein (SREBP) 1384
- Streptococcus*
  - group B *Streptococcus* (GBS) 83
  - Streptococcus agalactiae* 83
  - Streptococcus pneumoniae* 10, 83, 191, 420, 732, 1179, 1353
  - Streptococcus pyogenes* 21, 1353, 1426
- stress responses 815
- stroke 1280
- stromal cells 591
- stromal vascular fraction (SVF) 1199
  - cells 1200
- Strongyloides venezuelensis* 345
- SubAB-mediated suppression 89
- subcapsular sinus (SCS) 226
- subfornical organ (SFO) 871
- substance P (SP) 110
- subtilase cytotoxin (SubAB) 89
- successive redox reactions 699
- succinate 954
- sulfhydryl
  - free groups 709
- sulfur-based radicals 706

- sulfur-containing amino acids 707
  - sulfur oxidases (SOX) 707
  - superantigens 1068
  - superoxide 459, 700
  - superoxide dismutase (SOD) 137, 696, 916, 1319
    - SOD1 1264
    - SOD3 1186
  - suppressor-of-cytokine signaling (SOCS) 232, 1371, 1523
  - surface markers 370
  - surfactant proteins 734
    - protein D 182
  - Surviving Sepsis Campaign (SSC) 1037
  - synaptic plasticity 767
  - synthetic dipalmitoylated lipopeptide 27
  - systemic autoimmunity 1388
  - systemic hypotension, sepsis-induced 1307
  - systemic inflammatory response 836, 1200, 1583, 1597
    - syndrome 106, 1037, 1301, 1428
  - systemic lupus erythematosus (SLE) 186, 426, 792, 802, 995, 1054, 1392, 1476, 1674
    - aberrant cell death 1075
    - adjuvant mimicry leading to pseudoantiviral immunity 1075
    - autoreactive lymphocyte clones 1076
    - environmental factors promoting systemic lupus erythematosus activity 1076
    - erythematosus 580
    - pathomechanisms 1075
  - systemic onset juvenile arthritis (sJIA) 497
  - systems pharmacology 1676
- t**
- tachykinin NK1 receptors 111
  - tacrolimus 1673
  - TANK-binding kinase 1 (TBK1) 180
  - T-bet 341, 366, 406
  - T-bet<sup>+</sup> ILC3s 344
  - T-box transcription factor 366
  - T-cell 61, 280, 315, 341, 342, 396, 533, 536, 539, 629, 633, 638, 639, 785, 921, 947, 954, 971, 1150, 1151, 1228, 1279, 1316, 1343
    - anergy 299
    - autoantigen 1097
    - clonal deletion of 1056
    - clones 365
    - compartments 1154
    - effector and regulatory 529
    - factor 1 (TCF-1) 342
    - growth factor 590
    - immunity 792
    - immunoglobulin domain and mucin domain 3 (TIM3) 1431
    - mediated inflammatory disease 1099
    - memory 529
    - Naïve T cells 289
    - polarization 365
    - receptor 637, 659, 1004, 1056, 1076, 1666
      - induced clonal deletion 1379
      - induced expression of members of the TNF superfamily (TNFSF) 1385
      - ligation 1384
      - signaling 366
      - transgenic mice 1059
    - suppression 226
    - transfer 460
    - vaccination 819
  - Tconv cells 299
  - tertiary lymphoid organs (TLOs) 1072
  - testosterone, reducing TLR-4 expression by macrophage and monocytes 919
  - tetanus toxoid vaccine 146
  - tetrahydrobiopterin (BH<sub>4</sub>) 703
  - TF. *see* tissue factor (TF)
  - T follicular helper cells 366
  - Th1 cell 365, 366, 639, 659
    - cytokines 469
    - IL-1-β 103
    - differentiation

- PGE2-EP2/EP4-mediated facilitation, role of 661
    - effector CD4<sup>+</sup> T cells 299
    - master regulator transcription factor 639
    - mediated signals 553
    - polarization 1097
  - Th2 cell 365, 366, 634, 659, 996, 1203
    - cytokines 469, 558, 665, 1070
    - response 496
    - differentiation 374
    - driven allergic-induced asthma 559
    - immunity 293
    - mediated allergic inflammation 366, 663
    - produced IL-5 increased circulating eosinophils 366
    - T<sub>H</sub>2-associated innate and adaptive immunity 345
  - Th9 cell 375
    - associated cytokines and chemokines 371
    - associated effector molecules 381
    - differentiation 374, 377
      - cytokines and costimulators required for differentiation 377
    - Th9 biology, factors required for promotion of 380
    - transcription factors for differentiation 379
  - in disease helpful and unhelpful 371
  - driven allergic-induced asthma 559
  - function of 369
  - inducing
    - cell surface ligands 369
    - cytokines, additional 368
  - introduction to 367
  - responses, therapies potentially beneficial in modulating 378
  - targeting therapeutically 377
- Th17 cell 395, 396, 551, 555, 640, 659, 1475
  - during chronic inflammation 405
  - clinical targeting of 407
  - cytokines acting on 401
    - IL-23 401
    - IL-27 401
  - cytokines and chemokines produced by 399
    - CCL20 400
    - IL-21 400
    - IL-22 400
    - IL-17A and IL-17F 399
  - differentiation of 396
    - circulating vs. tissue phenotypes 398
    - in humans 397
    - in mice 396
    - pathogenic Th17 cells 398
  - effector CD4<sup>+</sup> T cells 299
    - and inflammatory diseases 401
      - arthritic diseases 402
      - inflammatory bowel diseases 403
      - multiple sclerosis 403
      - psoriasis 402
    - T<sub>H</sub>17-associated cytokines 341, 344
    - phenotypes 399
      - during chronic inflammation, differentiation, recruitment, and maintenance of 403
    - plasticity of 405, 406
    - polarization 1092
  - T-helper cell 341, 1094
    - lineage memory cells 591
    - subtype participation in autoimmunity 595
  - therapeutic interventions 1210, 1265
  - thermal hyperalgesia 655
  - thermoafferent pathway 865
  - thermoregulatory 863
    - effectors 863
    - system 863
    - thresholds 864
  - thermosensors 864
  - thiazolidinediones (TZDs) 1210
    - adipose effects of 1236
    - insulin sensitizing effect 1236
  - thioredoxin (TRX) 138
  - thiyl radicals (R-S<sup>•</sup>) 706
  - threonine amino acid residues 440
  - threshold temperatures 863
  - thrombelastography (TEG) 846

- thrombin 733, 1595  
     activatable fibrinolysis inhibitor (TAFI) 840  
 thrombocytopenia 425, 426, 800, 995  
 thrombocytosis 425  
 thrombolysis agent 1317  
 thrombomodulin (TM) 840, 1590  
     bound thrombin 841  
     TM-1 1525  
 thrombotic microangiopathies 801  
 thromboxane A2 (TxA2) 459  
     induced vasoconstriction 461  
     synthase 460  
     TP signaling 663  
 Thr308, phosphorylation of 1381  
 Thr<sup>37</sup> residue of Rho 88  
 thymic DC 1062  
 thymic regulatory T cells (tTreg) 298, 1378  
 thymic self-ligands 1378  
 thymic stromal lymphopoietin (TSLP) 996  
 thymocytes 224  
 thymus 1057, 1065  
     derived T<sub>REGS</sub> (tT<sub>REGS</sub>) 1379  
 thyroid hormones 915, 916  
 thyroxine (T4; 3,5,3',5'-tetraiodothyronine) 915  
 tie-2-mediated phosphorylation 467  
 timeline of autoantibody-positive rheumatoid arthritis (RA) 1108  
 TIR. *see* toll-interleukin receptor (TIR)  
 TIR-containing adapter protein (TIRAP) 1370  
 tissue damage 787, 915, 1363  
 tissue factor (TF) 464  
     eomesodermin 341  
     inhibitors 1316  
     pathway inhibitor 732, 837  
     protease inhibitor (TFPI) 739, 841  
 tissue ILCs homeostasis 345  
 tissue inhibitor of metalloproteinase 1 (TIMP1) 1208  
 tissue injury 629  
 tissue metaplasia 663  
 tissue remodeling 663  
 tissue repair 1355, 1517  
     anti-inflammatory cytokines 1523  
     cellular effectors of resolution 1524  
     chemokines regulate leukocyte recruitment 1520  
     complement cascade 1519  
     extracellular matrix 1525  
     fibroblast activation/scar formation 1526  
     inflammatory response 1517  
     leukocyte adhesion cascade 1523  
     leukocyte recruitment 1521  
     macrophages 1521  
     negative regulation of cytokine signaling 1523  
     pathways 790  
     postinfarction inflammation 1523  
     proinflammatory cytokines 1519  
     repression/resolution of inflammation 1522  
     role of neutrophils 1522  
     tissue-specific events leading to regeneration 1525  
*Tityus serrulatus* venom 106  
 TL1A/DR3 interaction 534  
 TLR. *see* toll-like receptors (TLR)  
 TNF. *see* tumor necrosis factor (TNF)  
 tocilizumab 407, 580, 1343  
 tofacitinib 1343  
 tolerance 1159  
     and accommodation of blood group mismatched transplants 1160  
 tolerogenic dendritic cells 596, 825, 1062  
 toll-interleukin receptor (TIR) 479, 1430, 1590  
     toll interleukin-1 receptor domain-containing adapter-inducing interferon- $\beta$  (TRIF) pathway 59  
 toll-like receptors (TLR) 24, 105, 138, 150, 176–181, 220, 275, 441, 468, 551, 594, 796, 821, 974, 997, 1097, 1152, 1232, 1281, 1282, 1315, 1351, 1423, 1488, 1518, 1541, 1590, 1664  
     agonists 144

- cell surface-bound TLRs 177
- endosomal TLRs 178
- humans TLR4 expression 1153
- ligands 145, 296, 479, 602, 916
- MyD88-dependent signaling pathway 179
- signaling 601
  - pathway 1370, 1371
- signaling pathway 180
- TLR signaling 179
- TLR2 34, 58, 151, 1426, 1474
  - mediated cell activation 34
  - stimulation 1264
- TLR3 152, 153
  - ligands/immunogenicity 152
  - dependent signaling 1264
- TLR4 153
  - deficient mice 64
  - inhibitors 1320
  - MyD88 signaling pathway 105, 1353
- TLR5 154
- TLR 7/8 154, 155
  - tolerizes cells 1426
- TLR9 156, 157
  - agonist CpG ODN 147
  - clinical activity 156
  - ligands 156
  - safety 157
  - transfected HEK cells 31
- TRIF signaling pathway 179
- vaccine adjuvants targeting
  - clinical activity 151, 153, 155
  - innate immune system 150
  - safety 152–155
- toxins blocking protein synthesis 88
- Toxoplasma gondii* 36, 178, 768, 1426
- TOX protein 342
- traditional Chinese medicine (TCM) 1661
- transcription activators 532, 921
- transcription factors 315, 341, 366, 395, 1315
- transforming growth factor (TGF) 262, 549, 734, 1328, 1385
  - TGF  $\beta$  467, 676, 1368
    - activated kinase 179, 1385, 1430
    - TGF $\beta$ /BMP signaling 1121
- transgenic mice expressing human IL-37 (IL37-tg) 501
- transient receptor potential V1 (TRPV1) 668
- transit-amplifying cell (TAC) 438
- transmembrane activator calcium modulator 536
- transplantation 1203
  - modulating inflammation to improve 1163
- treatment 1162
  - azathioprine 1162
  - CTLA4-Ig 1163
  - cyclosporine A 1162
  - monoclonal antibodies 1163
- $\Delta$ 10-trans-RvD2 isomer 1456
- transsulfuration pathway 707
- traumatic brain injury 1150
- Treg. *see* regulatory T cells (Treg)
- trehalose dimycolate (TDM) 185
- triacylated lipopeptide 25
- Trichuris muris* 345, 558
- trigeminal nerve 864
- triggering receptor expressed on myeloid cells-1 (TREM-1) 38, 1548, 1591
  - upregulated expression 1548
- triglycerides 1207, 1227
- trimethylamine-*N*-oxide (TMAO) 1288
- trinitrobenzene sulfonic acid (TNBS) 552, 661
  - induced colitis 494
- Tripterygium wilfordii* 1677
- Tripterygium wilfordii* Hook F 1674
- TRX interacting protein (TXNIP) 138
- Trypanosoma cruzi* 550
  - infections 35
- trypanosomatidae DNAs 62
- TSH administration 916
- T suppressor cells 1377
- tuberous sclerosis complex (TSC) 1381
- tubular cell apoptosis 1307
- tubulin 818
- tubulointerstitial fibrosis (TIF) 676

- tumor
    - antigen MAGE-3 157
    - associated macrophages 229
    - immunity 372
    - progression 220
    - regression 235, 1394
  - tumor necrosis factor (TNF) 21, 103, 109, 274, 397, 530, 732, 768, 791, 834, 837, 862, 1000, 1096, 1176, 1199, 1330, 1425, 1428, 1519, 1543
    - biological roles 530
    - converting enzyme (TACE) 34, 530
    - gene 1330
      - molecule, characterization of 532
    - IFN- $\gamma$  1228
    - immunoblockade 465
    - induced gene expression 658
    - mechanisms of action 531
    - promoter 1338
    - related apoptosis-inducing ligand receptor 1371
    - role in neuronal inflammation 538
    - role on inflammatory bowel diseases 537
    - signaling 1590
    - soluble 530
    - superfamily
      - actions of 531
      - members 540
    - synthesis 1520
  - tumor necrosis factor receptor (TNFR) 529, 530, 532, 1385
    - associated factor 550
    - interactions 538
    - superfamily 529, 532
      - BAFF-R-BAFF 536
      - DcR3 535
      - Fas ligands 534
      - GITRL 537
      - OX40 or ACT35 or CD134 or TNFRSF4 536
      - TL1A 533
      - TRAIL 535
      - TWEAK 535
    - TNFR-1 531
    - TNFR-associated death domain (TRADD) 529
    - TNFR-associated factor (TRAF) 1371, 1430
    - TNFRSF interactions 538
      - TNFRSF1B encoding receptor 1331
  - TxA2. *see* thromboxane A2 (TxA2)
  - typhoid vaccine 4
  - tyrosine 186
    - autophosphorylation 1231
    - phosphorylation 1230, 1231
- U**
- ubiquitin E3 ligase 822
  - ulcerative colitis (UC) 374, 400, 457, 460, 537, 540, 1336
  - ultrasound 1573
  - ultraviolet and/or ionizing radiation 696
  - uncoupling proteins 699
  - unfolded protein response (UPR) 89
  - unilateral ureteral obstruction (UUO) 675
  - uric acid 185, 711
  - ustekinumab 352, 407, 555
  - uveitis 499
  - UV-inactivated virus 11
  - UV-treated fibroblasts 63
- V**
- vaccination
    - with HSP60-derived peptide p227 824
    - immunogenicity 143
      - against tumor antigens 1394
    - target toll-like receptors 150
      - clinical activity 151, 153, 155
      - innate immune system 150
      - safety 152–155, 157
    - TLR2 151
    - TLR3 ligands/immunogenicity 152
    - TLR4 153
    - TLR5 154
    - TLR7/8 154, 155
    - TLR 9 156

- vaccinia virus (VV) 317  
 vagus nerve 864  
   stimulation (VNS) 1491  
 valine 46 503  
 vascular adhesion protein 1 792, 1578  
 vascular cell adhesion molecule 1  
   (VCAM-1) 1207, 1474  
 vascular disease, in type 2  
   diabetes 1234  
 vascular endothelial (VE)  
   cadherin (cadherin-5) 469  
 vascular endothelial growth factor  
   (VEGF) 109, 220, 274, 465,  
   657, 1118, 1428  
   depleting antibodies 465  
   proteolytic modification 466  
   receptor 466  
   receptor 2 468  
     activity 467  
   VEGF-A isoforms 466  
   VEGF-A-mediated angiogenic  
     signaling 468  
   VEGF/VEGFR complexes 466  
 vascularization 636  
 vasculitis 792, 799, 802, 1567, 1575  
   detected by [<sup>18</sup>F]FDG PET/CT 1576  
   lesions of 799  
 vasoactive intestinal peptide  
   (VIP) 1496  
 vasodilation 112  
 vasomotor dysfunction 458–460  
   angiogenesis/vasculogenesis 465  
   endothelial cell-dependent  
     vasoactivity 459  
   endothelium-dependent vasoactivity  
     in IBD 460  
   enhanced thrombosis 463  
   junctional 468  
   leukocyte–endothelial cell  
     adhesion 461  
   vascular smooth muscle contraction/  
     relaxation 459  
 VEGF. *see* vascular endothelial growth  
   factor (VEGF)  
 venom-induced inflammation 99  
 venomous animals 99  
   scorpions 105  
 venous congestion 1308  
 ventilator-associated pneumonia  
   (VAP) 1335  
 vesicular stomatitis virus (VSV) 34  
 vespids  
   inflammation induced by  
     venoms 110–111  
   venoms 111  
 vessel wall inflammation,  
   chronic 792  
*Vibrio cholerae* 83  
   vaccine 146  
 Viperidae family 100  
 viral IL-6 575  
 viral IL-18BP, natural  
   neutralization 497  
 viral infections 1395, 1398  
 virosomes, nano/microparticles 148  
 virtual screening 1676  
 virulence factors 1584  
 virus-associated inflammatory PD  
   models 1260  
 virus-induced  
   immunopathology 1396  
 visceral adipose tissue (VAT) 322,  
   1389  
   endothelial cells 1205  
 visceral epithelial cell (VEC) 800  
 visceral fat 1226  
 visfatin 926  
 vitamin A deficiency 347  
 vitamin C (ascorbic acid) 710  
 vitamin D 347  
 vitamin D3 (1,25-dihydroxyvitamin  
   D3) 825  
 vitamin K deficiency 846  
 von Hippel–Lindau protein  
   (VHL) 134  
   tumor suppressor gene 134  
 von Willebrand factor 836, 845, 1154  
   cleaving protease 837
- W**
- Warburg effect 135, 1383  
 warts, hypogammaglobulinemia,  
   infections, and myelokathexis  
   (WHIM) syndrome 636

- Waterhouse-Friderichsen syndrome 833
  - WEHI164 clone 532
  - Weibel-Palade storage granules 1154
  - West Nile virus (WNV) 317
  - white adipose tissue (WAT) 922
    - mast cells 1204
  - Willebrand factor 836
    - multimers 1595
  - Willow tree 1672
  - Wnt agonist R-spondin-1 444
  - Wnt/beta-catenin 1212
    - signaling pathway 538
  - Wnt inhibitory factor (WIF) 444
  - Wnt-receptor complex 443
  - Wnt signaling 444
    - pathway 438
  - wound healing, resolution of 1455
  - WSXWS amino acid motif 598
- x**
- xanthine oxidase 700, 716, 976, 1314
  - XIAP gene mutations 497
  - Xigris 796
- y**
- yellow fever virus 33
- z**
- zeta chain-associated protein kinase 70
    - (Zap70) deficiency 1065
  - zinc metalloproteinase (Zmp) 957
  - zonula occludens (ZO) 469, 733
  - zymosan-induced peritonitis 1498